

Rec'd PCT/PTO 04 OCT 2004

REC'D: 09 MAY 2003

WIPO PCT

PI 1005246

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

May 06, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/370,827

FILING DATE: April 08, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/10632

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. R. GRANT
Certifying Officer

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

04-09-U

A/PROV

SUBSTITUTE for Provisional Application for Patent Cover Sheet PTO/SB/16 (10-01)
 and for use through 10/31/2002. OMB 0651-0032
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

DOCKET NUMBER

21075PV

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Stanley F.	Barnett	North Wales, Pennsylvania
Deborah	DeFeo-Jones	Lansdale, Pennsylvania
Kathleen M.	Haskell	Colmar, Pennsylvania
Hans E.	Huber	Lansdale, Pennsylvania
Deborah D.	Nahas	Perkasie, Pennsylvania
Craig W.	Lindsley	Schwenksville, Pennsylvania
Zhijian	Zhao	Lansdale, Pennsylvania

☐ Additional inventors are being named on the separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

A METHOD OF TREATING CANCER

CORRESPONDENCE ADDRESS

Direct all Correspondence to:

Merck & Co., Inc.
 Patent Department - RY60-30
 P.O. Box 2000
 Rahway

☒ Customer Number

000210

STATE

New Jersey

ZIP CODE

07065

COUNTRY

U.S.A.

ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification

Number of Pages

94

☐ CD(s), Number☐ Drawing(s)

Number of Sheets

0

☐ Other (specify)☐ Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)

☐ A check or money order is enclosed to cover the filing fees☒ The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:

13-2755

FILING FEE
AMOUNT (\$)

\$160.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

Date 04/08/2002

TYPED or PRINTED NAME David A. Muthard

TELEPHONE (732) 594-3903

REGISTRATION NO.
(if appropriate)

35,297

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT April 8, 2002

EXPRESS MAIL NO. EL920630623US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE
 UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
 ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
 FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY

DATE April 8, 2002

In Duplicate

Computer generated form "Transmittal Form-FV" (Application Filing Folder) Merck & Co., Inc., 10/05/2001

5 TITLE OF THE INVENTION
A METHOD OF TREATING CANCER

BACKGROUND OF THE INVENTION

10 The present invention relates to methods of treating cancer by selectively inhibiting one or more isoforms of Akt (also known as PKB, and referred to herein as either Akt or Akt/PKB). The present invention also relates to a method of identifying such compounds.

15 Apoptosis (programmed cell death) plays essential roles in embryonic development and pathogenesis of various diseases, such as degenerative neuronal diseases, cardiovascular diseases and cancer. Recent work has led to the identification of various pro- and anti-apoptotic gene products that are involved in the regulation or execution of programmed cell death. Expression of anti-apoptotic genes, such as Bcl2 or Bcl-x_L, inhibits apoptotic cell death induced by various stimuli. On the other hand, expression of pro-apoptotic genes, such as Bax or Bad, leads to
20 programmed cell death (Aams et al. *Science*, 281:1322-1326 (1998)). The execution of programmed cell death is mediated by caspase -1 related proteinases, including caspase-3, caspase-7, caspase-8 and caspase-9 etc (Thorneberry et al. *Science*, 281:1312-1316 (1998)).

25 The phosphatidylinositol 3'-OH kinase (PI3K)/Akt/PKB pathway appears important for regulating cell survival/cell death (Kulik et al. *Mol. Cell. Biol.* 17:1595-1606 (1997); Franke et al, *Cell*, 88:435-437 (1997); Kauffmann-Zeh et al. *Nature* 385:544-548 (1997) Hemmings *Science*, 275:628-630 (1997); Dudek et al., *Science*, 275:661-665 (1997)). Survival factors, such as platelet derived growth factor (PDGF), nerve growth factor (NGF) and insulin-like growth factor-1 (IGF-1),
30 promote cell survival under various conditions by inducing the activity of PI3K (Kulik et al. 1997, Hemmings 1997). Activated PI3K leads to the production of phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)-P3), which in turn binds to, and promotes the activation of, the serine/threonine kinase Akt, which contains a pleckstrin homology (PH)-domain (Franke et al *Cell*, 81:727-736 (1995); Hemmings
35 *Science*, 277:534 (1997); Downward, *Curr. Opin. Cell Biol.* 10:262-267 (1998), Alessi et al., *EMBO J.* 15: 6541-6551 (1996)). Specific inhibitors of PI3K or dominant negative Akt/PKB mutants abolish survival-promoting activity of these growth factors or cytokines. It has been previously disclosed that inhibitors of PI3K (LY294002 or wortmannin) blocked the activation of Akt/PKB by upstream kinases.

- 5 In addition, introduction of constitutively active PI3K or Akt/PKB mutants promotes cell survival under conditions in which cells normally undergo apoptotic cell death (Kulik et al. 1997, Dudek et al. 1997). Analysis of Akt levels in human tumors showed that Akt-2 is overexpressed in a significant number of ovarian (J. Q. Cheung et al. *Proc. Natl. Acad. Sci. U.S.A.* 89:9267-9271(1992)) and pancreatic cancers (J. Q. Cheung et al. *Proc. Natl. Acad. Sci. U.S.A.* 93:3636-3641 (1996)). Similarly, Akt3 was found to be overexpressed in breast and prostate cancer cell lines (Nakatani et al. *J. Biol. Chem.* 274:21528-21532 (1999)).

- The tumor suppressor PTEN, a protein and lipid phosphatase that specifically removes the 3' phosphate of PtdIns(3,4,5)-P3, is a negative regulator of the PI3K/Akt pathway (Li et al. *Science* 275:1943-1947 (1997), Stambolic et al. *Cell* 95:29-39 (1998), Sun et al. *Proc. Natl. Acad. Sci. U.S.A.* 96:6199-6204 (1999)). Germline mutations of PTEN are responsible for human cancer syndromes such as Cowden disease (Liaw et al. *Nature Genetics* 16:64-67 (1997)). PTEN is deleted in a large percentage of human tumors and tumor cell lines without functional PTEN show elevated levels of activated Akt (Li et al. supra, Guldberg et al. *Cancer Research* 57:3660-3663 (1997), Risinger et al. *Cancer Research* 57:4736-4738 (1997)).

- These observations demonstrate that the PI3K/Akt pathway plays important roles for regulating cell survival or apoptosis in tumorigenesis.

- 25 Three members of the Akt/PKB subfamily of second-messenger regulated serine/threonine protein kinases have been identified and termed Akt1/PKB α , Akt2/PKB β , and Akt3/PKB γ respectively. The isoforms are homologous, particularly in regions encoding the catalytic domains. Akt/PKBs are activated by phosphorylation events occurring in response to PI3K signaling. PI3K phosphorylates membrane inositol phospholipids, generating the second messengers phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate, which have been shown to bind to the PH domain of Akt/PKB. The current model of Akt/PKB activation proposes recruitment of the enzyme to the membrane by 3'-phosphorylated phosphoinositides, where phosphorylation of the regulatory sites of Akt/PKB by the upstream kinases occurs (B.A. Hemmings, *Science* 275:628-630 (1997); B.A. Hemmings, *Science* 276:534 (1997); J. Downward, *Science* 279:673-674 (1998)).

Phosphorylation of Akt1/PKB α occurs on two regulatory sites, Thr³⁰⁸ in the catalytic domain activation loop and on Ser⁴⁷³ near the carboxy terminus (D. R. Alessi et al. *EMBO J.* 15:6541-6551 (1996) and R. Meier et al. *J. Biol. Chem.*

5 272:30491-30497 (1997)). Equivalent regulatory phosphorylation sites occur in Akt2/PKB β and Akt3/PKB γ . The upstream kinase, which phosphorylates Akt/PKB at the activation loop site has been cloned and termed 3'-phosphoinositide dependent protein kinase 1 (PDK1). PDK1 phosphorylates not only Akt/PKB, but also p70 ribosomal S6 kinase, p90RSK, serum and glucocorticoid-regulated kinase (SGK),
 10 and protein kinase C. The upstream kinase phosphorylating the regulatory site of Akt/PKB near the carboxy terminus has not been identified yet, but a recent report implies a role for the integrin-linked kinase (ILK-1), a serine/threonine protein kinase, or autophosphorylation.

Inhibition of Akt activation and activity can be achieved by inhibiting
 15 PI3K with inhibitors such as LY294002 and wortmannin. However, PI3K inhibition has the potential to indiscriminately affect not just all three Akt isozymes but also other PH domain-containing signaling molecules that are dependent on PtdIns(3,4,5)-P3, such as the Tec family of tyrosine kinases. Furthermore, it has been disclosed that Akt can be activated by growth signals that are independent of PI3K.

20 Alternatively, Akt activity can be inhibited by blocking the activity of the upstream kinase PDK1. No specific PDK1 inhibitors have been disclosed. Again, inhibition of PDK1 would result in inhibition of multiple protein kinases whose activities depend on PDK1, such as atypical PKC isoforms, SGK, and S6 kinases (Williams et al. *Curr. Biol.* 10:439-448 (2000).

25 It is therefore an object of the instant invention to provide a method for treating cancer that comprises administering an inhibitor of Akt/PKB activity that selectively inhibits one or more of the Akt/PKB isoforms over the other isoform(s).

It is also an object of the present invention to provide a method for treating cancer that comprises administering an inhibitor of Akt/PKB activity that
 30 selectively inhibits one or more of the Akt/PKB isoforms and is dependent on the PH domain, the hinge region of the protein or both the PH domain and the hinge region for its inhibitory activity.

It is also an object of the instant invention to provide a method of identifying an inhibitor of PKB that selectively inhibits one or more of the Akt/PKB
 35 isoforms and is dependent on the PH domain for its inhibitory activity.

SUMMARY OF THE INVENTION

The instant invention provides for a method of treating cancer which comprises administering to a mammal an inhibitor of Akt/PKB activity that

208040-280409
 50370827-040802

5 selectively inhibits one or more of the Akt/PKB isoforms. The invention also provides for a method of inhibiting Akt/PKB activity by administering a compound that is an inhibitor of Akt/PKB activity that selectively inhibits one or more of the Akt/PKB isoforms and is dependent on the PH domain for its inhibitory activity. A method of identifying such selective inhibitors of Akt/PKB activity is also disclosed.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method of inhibiting Akt/PKB activity which comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound that selectively inhibits one or more of the Akt/PKB isoforms. The invention also relates to a method of treating cancer that comprises administering to a mammal in need thereof an inhibitor whose activity is dependent on the presence of the pleckstrin homology (PH) domain, the hinge region or both the PH domain and the hinge region of Akt.

Direct inhibition of one or more Akt isozymes provides the most specific means of regulating the PI3K/Akt pathway.

The term "inhibiting Akt/PKB activity" as used herein describes the decrease in the *in vitro* and *in vivo* biochemical modifications resulting from the phosphorylation of Akt by upstream kinases and/or the subsequent phosphorylation of downstream targets of Akt by activated Akt. Thus, the terms "inhibitor of Akt/PKB activity" and "inhibitor of Akt/PKB [isoforms]" describe an agent that, by binding to Akt, either inhibits the phosphorylation of Akt by upstream kinases (thereby reducing the amount of activated Akt) or inhibits the phosphorylation by activated Akt of protein targets of Akt, or inhibits both of these biochemical steps. In a preferred embodiment, the inhibitor utilized in the instant methods inhibits the phosphorylation of Akt by upstream kinases (thereby reducing the amount of activated Akt) and inhibits the phosphorylation by activated Akt of protein targets of Akt.

In an embodiment, the selective inhibitor useful in the instant method of treatment is selected from: a selective inhibitor of Akt 1, a selective inhibitor of Akt 2, a selective inhibitor of Akt3, a selective inhibitor of two of the three Akt isoforms or a selective inhibitor of all three Akt isoforms.

Preferably, the selective inhibitor useful in the instant method of treatment is selected from: a selective inhibitor of Akt 1, a selective inhibitor of Akt 2, a selective inhibitor of Akt 3, a selective inhibitor of both Akt 1 and Akt 2, a selective inhibitor of both Akt1 and Akt 3, or a selective inhibitor of both Akt 2 and

- 5 Akt 3. More preferably, the selective inhibitor useful in the instant method of treatment is selected from: a selective inhibitor of Akt 1, a selective inhibitor of Akt 2 or a selective inhibitor of both Akt 1 and Akt 2.

10 Preferably, the selective inhibitor useful in the instant method is a small organic molecule. The term "small organic molecule", as used herein, refers to a compound that is an organic molecule of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, nucleic acids, etc.). Preferred small organic molecules range in size up to about 2000 Da, and more preferably in size up to about 1000 Da.

15 The term "selective inhibitor" as used herein is intended to mean that the inhibiting compound exhibits greater inhibition against the activity of the indicated isoform(s) of Akt, when compared to the compounds inhibition of the activity of the other Akt isoform(s) and other kinases, such as PKA and PKC. Preferably, the selectively inhibiting compound exhibits at least about a 5 fold greater inhibition against the activity of the indicated isoform(s) of Akt. More preferably, the
20 selectively inhibiting compound exhibits at least about a 50 fold greater inhibition against the activity of the indicated isoform(s) of Akt.

In a second embodiment of the invention, the methods of treating cancer and inhibiting Akt comprise administering an inhibitor whose activity is dependent on the presence of the pleckstrin homology (PH) domain, the hinge region
25 or both the PH domain and the hinge region of Akt.

The PH domains and hinge regions of the three Akt isoforms, though presumably functionally equivalent in terms of lipid binding, show little sequence homology and are much less conserved than the catalytic domains. Inhibitors of Akt that function by binding to the PH domain, the hinge region or both are thus able to
30 discriminate between the three Akt isozymes.

A selective inhibitor whose inhibitory activity is dependent on the PH domain exhibits a decrease in *in vitro* inhibitory activity or no *in vitro* inhibitory activity against truncated Akt/PKB proteins lacking the PH domain.

35 A selective inhibitor whose inhibitory activity is dependent on the hinge region, the region of the proteins between the PH domain and the kinase domain (see Konishi *et al. Biochem. and Biophys. Res. Comm.* 216: 526-534 (1995), Figure 2, incorporated herein by reference), exhibits a decrease in *in vitro* inhibitory activity or no *in vitro* inhibitory activity against truncated Akt proteins lacking the PH domain and the hinge region or the hinge region alone.

5 The method of using such an inhibitor that is dependent on either the PH domain, the hinge region or both provides a particular advantage since the PH domains and hinge regions in the Akt isoforms lack the sequence homology that is present in the rest of the protein, particularly the homology found in the kinase domains (which comprise the catalytic domains and ATP-binding consensus sequences). It is therefore observed that certain inhibitor compounds, such as those described herein, are not only selective for one or two isoforms of Akt, but also are weak inhibitors or fail to inhibit other kinases, such as PKA and PKC, whose kinase domains share some sequence homology with the kinase domains of the Akt/PKB isoforms. Both PKA and PKC lack a PH domain and a hinge region.

10 Preferably, the selective inhibitor of the second embodiment is selected from: a selective inhibitor of Akt 1, a selective inhibitor of Akt 2 or a selective inhibitor of both Akt 1 and Akt 2.

15 In a sub-embodiment of the second embodiment, the selective inhibitor useful in the instant method of treatment is selected from: a selective inhibitor of Akt 1, a selective inhibitor of Akt 2, a selective inhibitor of Akt3 or a selective inhibitor of two of the three Akt isoforms.

20 In another sub-embodiment, the selective inhibitor of one or two of the Akt isoforms useful in the instant method of treatment is not an inhibitor of one or both of such Akt isoforms that have been modified to delete the PH domain, the hinge region or both the PH domain and the hinge region.

25 In another sub-embodiment, the selective inhibitor of all three Akt isoforms useful in the instant method of treatment is not an inhibitor of one, two or all of such Akt isoforms that have been modified to delete the PH domain, the hinge region or both the PH domain and the hinge region.

30 The present invention further relates to a method of identifying a compound that is a selective inhibitor of one or two of the Akt/PKB isoforms, or all three isoforms, whose inhibitory efficacy is dependent on the PH domain. The method comprises the steps of:

- 35 a) determining the efficacy of a test compound in inhibiting the activity of an Akt isoform;
- b) determining the efficacy of the test compound in inhibiting the activity of the Akt isoform that has been modified to delete the PH domain; and

- 5 c) comparing the activity of the test compound against the Akt isoform with the activity of the test compound against the modified Akt isoform lacking the PH domain.

The present invention also relates to a method of identifying a compound that is a selective inhibitor of one or two of the Akt/PKB isoforms, or all
10 three isoforms, whose inhibitory efficacy is dependent on the hinge region. The method comprises the steps of:

- a) determining the efficacy of a test compound in inhibiting the activity of an Akt isoform;
b) determining the efficacy of the test compound in inhibiting the activity of the
15 Akt isoform that has been modified to delete the PH domain;
c) determining the efficacy of the test compound in inhibiting the activity of the Akt isoform that has been modified to delete the PH domain and the hinge region; and
d) comparing the activity of the test compound against the Akt isoform, the
20 activity of the test compound against the modified Akt isoform lacking the PH domain, and the activity of the test compound against the modified Akt isoform lacking the PH domain and the hinge region.

The compounds that are identified by the methods described above as inhibitors of the activity of one or more Akt isoforms that are dependent on the
25 presence of either or both the PH domain or hinge region of the Akt isoform will be useful in the methods of treatment disclosed herein. Such compounds may further be useful as components in assay systems that may be used to identify other inhibitors of the activity of one or more Akt isoforms wherein the other inhibitors have inhibitory activity through selective binding and/or interaction with the kinase region of the Akt
30 isoform(s). Also useful as an assay component would be a PH domain and/or hinge region dependent inhibitor that is an irreversible inhibitor of the Akt isoform(s). Methods are well known in the art for determining whether the activity of an inhibitor of a biological activity or enzyme is reversible or irreversible.

It is understood that the modified Akt isoforms useful in the above
35 methods of identification may alternatively lack less than the full PH region and/or hinge region. For example, a modified Akt isoform may lack the full PH domain and a portion of the hinge region. It is also understood that the methods may alternatively comprise modified Akt isoforms wherein the PH domain and/or the hinge region are modified by a specific point mutation(s) in those amino acid sequences. Such a

5 method comprising a modified Akt isoform having a point mutation(s) in the PH domain and/or the hinge region may not only identify whether the activity of an inhibitor compound is dependent on the presence of the PH domain and/or the hinge region, but may also identify the specific site in the Akt isoform where the inhibitor compound interacts or binds with the protein.

10 The present invention is also directed to the cloning and expression of modified versions of the Akt isoforms that are useful in the methods of identifying inhibitor compounds described hereinabove. Specifically, modified Akt isoforms lacking only the PH domain (deletion of about aa 4-110 for Akt 1, deletion of about aa 4-110 for Akt 2 and deletion of about aa 4-109 for Akt 3) may be prepared by
15 techniques well known in the art. Similarly, modified Akt isoforms wherein both the PH domain and the hinge region are deleted (deletion of about aa 4-145 for Akt 1, deletion of about aa 4-147 for Akt 2 and deletion of about aa 4-143 for Akt 3) may be prepared by techniques well known in the art.

The present invention is further directed to the cloning and expression
20 of modified versions of the Akt isoforms wherein one or more point mutations are made to the amino acid sequences of the PH domain and the hinge region. Preferably, one or two point mutations are made to the amino acid sequences of the PH domain and the hinge region. Most preferably, one point mutation is made to the amino acid sequences of the PH domain and the hinge region.

25 The methods of the instant invention are useful in the treatment of cancer, in particular cancers associated with irregularities in the activity of PTEN, Akt and/or GSK3. Such cancers include, but are not limited to colon, prostate, colorectal, ovarian, pancreatic and breast cancer.

The compounds of this invention may be administered to mammals,
30 preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.

35 The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and

60370827-040802

5 such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for
10 example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets
15 may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a water soluble taste masking material such as hydroxypropylmethyl-cellulose or hydroxypropyl-cellulose, or a time delay material such as ethyl cellulose, cellulose acetate butyrate
20 may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyl-
25 eneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum
30 tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived
35 from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-

- 5 propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring agents, preservatives and antioxidants.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.

The pharmaceutical compositions may be in the form of a sterile injectable aqueous solutions. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.

The sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. For example, the active ingredient may be first dissolved in a mixture of soybean oil and

- 5 lecithin. The oil solution then introduced into a water and glycerol mixture and processed to form a microemulsion.

The injectable solutions or microemulsions may be introduced into a patient's blood-stream by local bolus injection. Alternatively, it may be advantageous to administer the solution or microemulsion in such a way as to maintain a constant circulating concentration of the instant compound. In order to maintain such a constant concentration, a continuous intravenous delivery device may be utilized. An example of such a device is the Deltec CADD-PLUS™ model 5400 intravenous pump.

- 15 The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension for intramuscular and subcutaneous administration. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

- 25 Compounds of Formula A may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.

30 For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula A are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)

- 35 The compounds useful in the instant method of treatment of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles and delivery devices, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

2003040 " 040802

5 As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specific amounts, as well as any product which results, directly or indirectly, from combination of the specific ingredients in the specified amounts.

10 The instant compounds may also be co-administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated.

 For example, instant compounds are useful in combination with known anti-cancer agents. Combinations of the presently disclosed compounds with other anti-cancer or chemotherapeutic agents are within the scope of the invention.

15 Examples of such agents can be found in *Cancer Principles and Practice of Oncology* by V.T. Devita and S. Hellman (editors), 6th edition (February 15, 2001), Lippincott Williams & Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved. Such anti-cancer agents include

20 the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic/cytostatic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors and angiogenesis inhibitors. The instant compounds are particularly useful when co-administered with radiation therapy.

25 "Estrogen receptor modulators" refers to compounds that interfere or inhibit the binding of estrogen to the receptor, regardless of mechanism. Examples of estrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyloxy)]phenyl]-2H-1-benzopyran-3-yl)-phenyl-2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone, and SH646.

30

 "Androgen receptor modulators" refers to compounds which interfere or inhibit the binding of androgens to the receptor, regardless of mechanism. Examples of androgen receptor modulators include, but are not limited to, finasteride

35 and other 5 α -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.

 "Retinoid receptor modulators" refers to compounds which interfere or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinoin, 13-cis-retinoic

- 5 acid, 9-cis-retinoic acid, α -difluoromethylornithine, ILX23-7553, trans-N-(4'-hydroxyphenyl) retinamide, and N-4-carboxyphenyl retinamide.

"Cytotoxic/cytostatic agents" refer to compounds which cause cell death or inhibit cell proliferation primarily by interfering directly with the cell's functioning or inhibit or interfere with cell myosis, including alkylating agents, tumor
10 necrosis factors, intercalators, hypoxia activatable compounds, microtubule inhibitors/microtubule-stabilizing agents, inhibitors of mitotic kinesins, anti-metabolites; biological response modifiers; hormonal/anti-hormonal therapeutic agents, hematopoietic growth factors, monoclonal antibody targeted therapeutic agents and topoisomerase inhibitors.

15 Examples of cytotoxic agents include, but are not limited to, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin,
20 cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methyl-pyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans, trans, trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(II)]bis[diamine(chloro)platinum (II)]tetrachloride, diarizidinylspermine, arsenic trioxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone,
25 pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755, and 4-demethoxy-3-deamino-3-aziridinyl-4-methylsulphonyl-daunorubicin (see WO 00/50032).

An example of a hypoxia activatable compound is tirapazamine.

30 Examples of microtubule inhibitors/microtubule-stabilizing agents include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincal leukoblastine, docetaxel, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl) benzene sulfonamide, anhydrovinblastine,
35 N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258, and BMS188797.

Some examples of topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exo-benzylidene-

- 5 chartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrzolo[3,4,5-kl]acridine-2-(6H)-propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':b,7]indolizino[1,2b]quinoline-10,13(9H,15H)dione, lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-
- 10 dimethylamino-2'-deoxy-etoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a, 5aB, 8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]-
- 15 phenanthridinium, 6,9-bis[(2-aminoethyl)amino]benzo[g]isoguinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrzolo[4,5,1-de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]
- 20 quinolin-7-one, and dimesna.

Examples of inhibitors of mitotic kinesins are described in PCT Publications WO 01/30768 and WO 01/98278.

- "Antiproliferative agents" includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001,
- 25 and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine, ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-dihydro-benzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)
- 30 urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-heptopyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b][1,4]thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo(7.4.1.0.0)-
- 35 tetradeca-2,4,6-trien-9-yl acetic acid ester, swainsonine, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-arabino furanosyl cytosine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and trastuzumab.

Examples of monoclonal antibody targeted therapeutic agents include those therapeutic agents which have cytotoxic agents or radioisotopes attached to a


- 5 cancer cell specific or target cell specific monoclonal antibody. Examples include Bexxar.

10 "HMG-CoA reductase inhibitors" refers to inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase. Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. For example, see the assays described or cited in U.S. Patent 4,231,938 at col. 6, and WO 84/02131 at pp. 30-33. The terms "HMG-CoA reductase inhibitor" and "inhibitor of HMG-CoA reductase" have the same meaning when used herein.

15 Examples of HMG-CoA reductase inhibitors that may be used include but are not limited to lovastatin (MEVACOR®; see U.S. Patent Nos. 4,231,938, 4,294,926 and 4,319,039), simvastatin (ZOCOR®; see U.S. Patent Nos. 4,444,784, 4,820,850 and 4,916,239), pravastatin (PRAVACHOL®; see U.S. Patent Nos. 4,346,227, 4,537,859, 4,410,629, 5,030,447 and 5,180,589), fluvastatin (LESCOL®; see U.S. Patent Nos. 5,354,772, 4,911,165, 4,929,437, 5,189,164, 5,118,853, 5,290,946 and 5,356,896), atorvastatin (LIPITOR®; see U.S. Patent Nos. 5,273,995, 20 4,681,893, 5,489,691 and 5,342,952) and cerivastatin (also known as rivastatin and BAYCHOL®; see US Patent No. 5,177,080). The structural formulas of these and additional HMG-CoA reductase inhibitors that may be used in the instant methods are described at page 87 of M. Yalpani, "Cholesterol Lowering Drugs", *Chemistry & Industry*, pp. 85-89 (5 February 1996) and US Patent Nos. 4,782,084 and 4,885,314.

25 The term HMG-CoA reductase inhibitor as used herein includes all pharmaceutically acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and therefor the use of such salts, esters, open-acid and lactone forms is included within the scope of this invention. An illustration of the

30 lactone portion and its corresponding open-acid form is shown below as structures I and II.



5

In HMG-CoA reductase inhibitors where an open-acid form can exist, salt and ester forms may preferably be formed from the open-acid, and all such forms are included within the meaning of the term "HMG-CoA reductase inhibitor" as used herein. Preferably, the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and most preferably simvastatin. Herein, the term "pharmaceutically acceptable salts" with respect to the HMG-CoA reductase inhibitor shall mean non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base, particularly those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium, as well as those salts formed from amines such as ammonia, ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1'-yl-methylbenz-imidazole, diethylamine, piperazine, and tris(hydroxymethyl)aminomethane. Further examples of salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamaote, palmitate, panthothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate.

5 Ester derivatives of the described HMG-CoA reductase inhibitor compounds may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.

10 "Prenyl-protein transferase inhibitor" refers to a compound which inhibits any one or any combination of the prenyl-protein transferase enzymes, including farnesyl-protein transferase (FPTase), geranylgeranyl-protein transferase type I (GGPTase-I), and geranylgeranyl-protein transferase type-II (GGPTase-II, also called Rab GGPTase). Examples of prenyl-protein transferase inhibiting compounds include (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (-)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, 5(S)-n-butyl-1-(2,3-dimethylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, (S)-1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-5-[2-(ethanesulfonyl)methyl]-2-piperazinone, 5(S)-n-Butyl-1-(2-methylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-2-methyl-5-imidazolylmethyl]-2-piperazinone, 1-(2,2-diphenylethyl)-3-[N-(1-(4-cyanobenzyl)-1H-imidazol-5-ylethyl)carbamoyl]piperidine, 4-{5-[4-hydroxymethyl]-4-(4-chloropyridin-2-ylmethyl)-piperidine-1-ylmethyl}-2-methylimidazol-1-ylmethyl} benzonitrile, 4-{5-[4-hydroxymethyl-4-(3-chlorobenzyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl}benzonitrile, 4-{3-[4-(2-oxo-2H-pyridin-1-yl)benzyl]-3H-imidazol-4-ylmethyl}benzonitrile, 4-{3-[4-(5-chloro-2-oxo-2H-[1,2']bipyridin-5'-ylmethyl)-3H-imidazol-4-ylmethyl}benzonitrile, 4-{3-[4-(2-oxo-1-phenyl-1,2-dihydropyridin-4-ylmethyl)-3H-imidazol-4-ylmethyl}benzonitrile, 18,19-dihydro-19-oxo-5H,17H-6,10:12,16-dimetheno-1H-imidazo[4,3-c][1,1,4]dioxazacyclo-nonadecine-9-carbonitrile, (±)-19,20-dihydro-19-oxo-5H-18,21-ethano-12,14-etheno-6,10-metheno-22H-benzo[d]imidazo[4,3-k][1,6,9,12]oxatriaza-cyclooctadecine-9-carbonitrile, 19,20-dihydro-19-oxo-5H,17H-18,21-ethano-6,10:12,16-dimetheno-22H-imidazo[3,4-h][1,8,11,14]oxatriazacycloeicosine-9-carbonitrile, and (±)-19,20-dihydro-3-methyl-19-oxo-5H-18,21-ethano-12,14-etheno-6,10-metheno-22H-benzo[d]imidazo[4,3-k][1,6,9,12]oxa-triazacyclooctadecine-9-carbonitrile.

5 Other examples of prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U.S. Patent No. 5,420,245, U.S. Patent No. 5,523,430, U.S. Patent No. 5,532,359, U.S. Patent No. 5,510,510, U.S. Patent No. 5,589,485, U.S. Patent
10 No. 5,602,098, European Patent Publ. 0 618 221, European Patent Publ. 0 675 112, European Patent Publ. 0 604 181, European Patent Publ. 0 696 593, WO 94/19357, WO 95/08542, WO 95/11917, WO 95/12612, WO 95/12572, WO 95/10514, U.S. Patent No. 5,661,152, WO 95/10515, WO 95/10516, WO 95/24612, WO 95/34535, WO 95/25086, WO 96/05529, WO 96/06138, WO 96/06193, WO 96/16443, WO
15 96/21701, WO 96/21456, WO 96/22278, WO 96/24611, WO 96/24612, WO 96/05168, WO 96/05169, WO 96/00736, U.S. Patent No. 5,571,792, WO 96/17861, WO 96/33159, WO 96/34850, WO 96/34851, WO 96/30017, WO 96/30018, WO 96/30362, WO 96/30363, WO 96/31111, WO 96/31477, WO 96/31478, WO 96/31501, WO 97/00252, WO 97/03047, WO 97/03050, WO 97/04785, WO
20 97/02920, WO 97/17070, WO 97/23478, WO 97/26246, WO 97/30053, WO 97/44350, WO 98/02436, and U.S. Patent No. 5,532,359. For an example of the role of a prenyl-protein transferase inhibitor on angiogenesis see European J. of Cancer, Vol. 35, No. 9, pp.1394-1401 (1999).

25 "Angiogenesis inhibitors" refers to compounds that inhibit the formation of new blood vessels, regardless of mechanism. Examples of angiogenesis inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors of the tyrosine kinase receptors Flt-1 (VEGFR1) and Flk-1/KDR (VEGFR2), inhibitors of epidermal-derived, fibroblast-derived, or platelet derived growth factors, MMP (matrix metalloprotease) inhibitors, integrin blockers, interferon- α , interleukin-
30 12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti-inflammatories (NSAIDs) like aspirin and ibuprofen as well as selective cyclooxygenase-2 inhibitors like celecoxib and rofecoxib (PNAS, Vol. 89, p. 7384 (1992); JNCI, Vol. 69, p. 475 (1982); Arch. Ophthalmol., Vol. 108, p.573 (1990); Anat. Rec., Vol. 238, p. 68 (1994); FEBS Letters, Vol. 372, p. 83 (1995); Clin. Orthop. Vol. 313, p. 76 (1995); J. Mol. Endocrinol., Vol. 16, p.107 (1996); Jpn. J. Pharmacol., Vol. 75, p. 105 (1997); Cancer Res., Vol. 57, p. 1625 (1997); Cell, Vol. 93, p. 705 (1998); Intl. J. Mol. Med., Vol. 2, p. 715 (1998); J. Biol. Chem., Vol. 274, p. 9116 (1999)),
35 steroidal anti-inflammatories (such as corticosteroids, mineralocorticoids, dexamethasone, prednisone, prednisolone, methylpred, betamethasone),

5 carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl-fumagillol, thalidomide, angiostatin, troponin-1, angiotensin II antagonists (see Fernandez et al., J. Lab. Clin. Med. 105:141-145 (1985)), and antibodies to VEGF (see, Nature Biotechnology, Vol. 17, pp.963-968 (October 1999); Kim et al., Nature, 362, 841-844 (1993); WO 00/44777; and WO 00/61186).

10 Other therapeutic agents that modulate or inhibit angiogenesis and may also be used in combination with the compounds of the instant invention include agents that modulate or inhibit the coagulation and fibrinolysis systems (see review in *Clin. Chem. La. Med.* 38:679-692 (2000)). Examples of such agents that modulate or inhibit the coagulation and fibrinolysis pathways include, but are not limited to,
 15 heparin (see *Thromb. Haemost.* 80:10-23 (1998)), low molecular weight heparins and carboxypeptidase U inhibitors (also known as inhibitors of active thrombin activatable fibrinolysis inhibitor [TAFIa]) (see *Thrombosis Res.* 101:329-354 (2001)). TAFIa inhibitors have been described in U.S. Ser. Nos. 60/310,927 (filed August 8, 2001) and 60/349,925 (filed January 18, 2002).


20 As described above, the combinations with NSAID's are directed to the use of NSAID's which are potent COX-2 inhibiting agents. For purposes of this specification an NSAID is potent if it possess an IC_{50} for the inhibition of COX-2 of $1\mu M$ or less as measured by cell or microsomal assays.

The invention also encompasses combinations with NSAID's which
 25 are selective COX-2 inhibitors. For purposes of this specification NSAID's which are selective inhibitors of COX-2 are defined as those which possess a specificity for inhibiting COX-2 over COX-1 of at least 100 fold as measured by the ratio of IC_{50} for COX-2 over IC_{50} for COX-1 evaluated by cell or microsomal assays. Such compounds include, but are not limited to those disclosed in U.S. Patent 5,474,995,
 30 issued December 12, 1995, U.S. Patent 5,861,419, issued January 19, 1999, U.S. Patent 6,001,843, issued December 14, 1999, U.S. Patent 6,020,343, issued February 1, 2000, U.S. Patent 5,409,944, issued April 25, 1995, U.S. Patent 5,436,265, issued July 25, 1995, U.S. Patent 5,536,752, issued July 16, 1996, U.S. Patent 5,550,142, issued August 27, 1996, U.S. Patent 5,604,260, issued February 18, 1997, U.S.
 35 5,698,584, issued December 16, 1997, U.S. Patent 5,710,140, issued January 20, 1998, WO 94/15932, published July 21, 1994, U.S. Patent 5,344,991, issued June 6, 1994, U.S. Patent 5,134,142, issued July 28, 1992, U.S. Patent 5,380,738, issued January 10, 1995, U.S. Patent 5,393,790, issued February 20, 1995, U.S. Patent 5,466,823, issued November 14, 1995, U.S. Patent 5,633,272, issued May 27, 1997,


- 5 and U.S. Patent 5,932,598, issued August 3, 1999, all of which are hereby incorporated by reference.

Inhibitors of COX-2 that are particularly useful in the instant method of treatment are:

- 10 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone; and



- 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine;




15



or a pharmaceutically acceptable salt thereof.

- General and specific synthetic procedures for the preparation of the COX-2 inhibitor compounds described above are found in U.S. Patent No. 5,474,995, issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, and U.S. Patent No. 6,001,843, issued December 14, 1999, all of which are herein incorporated by reference.

- Compounds that have been described as specific inhibitors of COX-2 and are therefore useful in the present invention include, but are not limited to, the following:



5



or a pharmaceutically acceptable salt thereof.

- 10 Compounds which are described as specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: WO 94/15932, published July 21, 1994, U.S. Patent No. 5,344,991, issued June 6, 1994, U.S. Patent No. 5,134,142, issued July 28, 1992, U.S. Patent No. 5,380,738, issued January 10, 1995, U.S. Patent No. 5,393,790, 15 issued February 20, 1995, U.S. Patent No. 5,466,823, issued November 14, 1995,

- 5 U.S. Patent No. 5,633,272, issued May 27, 1997, and U.S. Patent No. 5,932,598, issued August 3, 1999.

Compounds which are specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein
 10 incorporated by reference: U.S. Patent No. 5,474,995, issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, U.S. Patent No. 6,001,843, issued December 14, 1999, U.S. Patent No. 6,020,343, issued February 1, 2000, U.S. Patent No. 5,409,944, issued April 25, 1995, U.S. Patent No. 5,436,265, issued July 25, 1995, U.S. Patent No. 5,536,752, issued July 16, 1996, U.S. Patent No.
 15 5,550,142, issued August 27, 1996, U.S. Patent No. 5,604,260, issued February 18, 1997, U.S. Patent No. 5,698,584, issued December 16, 1997, and U.S. Patent No. 5,710,140, issued January 20, 1998.

Other examples of angiogenesis inhibitors include, but are not limited to, endostatin, ukrain, ranpirnase, IM862, 5-methoxy-4-[2-methyl-3-(3-methyl-2-
 20 butenyl)oxiranyl]-1-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-1H-1,2,3-triazole-4-carboxamide, CM101, squalamine, combretastatin, RPI4610, NX31838, sulfated mannopentaose phosphate, 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolocarbonyl-
 imino[N-methyl-4,2-pyrrole]-carbonylimino]-bis-(1,3-naphthalene disulfonate), and
 25 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone (SU5416).

As used above, "integrin blockers" refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the $\alpha_v\beta_3$ integrin, to compounds which selectively antagonize, inhibit or counter-
 act binding of a physiological ligand to the $\alpha_v\beta_5$ integrin, to compounds which
 30 antagonize, inhibit or counteract binding of a physiological ligand to both the $\alpha_v\beta_3$ integrin and the $\alpha_v\beta_5$ integrin, and to compounds which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial cells. The term also refers to antagonists of the $\alpha_v\beta_6$, $\alpha_v\beta_8$, $\alpha_1\beta_1$, $\alpha_2\beta_1$, $\alpha_5\beta_1$, $\alpha_6\beta_1$ and $\alpha_6\beta_4$ integrins. The term also refers to antagonists of any combination
 35 of $\alpha_v\beta_3$, $\alpha_v\beta_5$, $\alpha_v\beta_6$, $\alpha_v\beta_8$, $\alpha_1\beta_1$, $\alpha_2\beta_1$, $\alpha_5\beta_1$, $\alpha_6\beta_1$ and $\alpha_6\beta_4$ integrins.

Some specific examples of tyrosine kinase inhibitors include N-(trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one, 17-(allylamino)-17-demethoxygeldanamycin, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline,

- 5 N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, BIBX1382, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, SH268, genistein, STI571, CEP2563, 4-(3-chlorophenylamino)-5,6-dimethyl-7H-pyrrolo [2,3-d]pyrimidinemethane sulfonate, 4-(3-bromo-4-hydroxyphenyl)amino-6,7-
10 dimethoxyquinazoline, 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, SU6668, STI571A, N-4-chlorophenyl-4-(4-pyridylmethyl)-1-phthalazinamine, and EMD121974.

- Combinations with compounds other than anti-cancer compounds are also encompassed in the instant methods. For example, combinations of the instantly
15 claimed compounds with PPAR- γ (i.e., PPAR-gamma) agonists and PPAR- δ (i.e., PPAR-delta) agonists are useful in the treatment of certain malignancies. PPAR- γ and PPAR- δ are the nuclear peroxisome proliferator-activated receptors γ and δ . The expression of PPAR- γ on endothelial cells and its involvement in angiogenesis has been reported in the literature (see *J. Cardiovasc. Pharmacol.* 1998; 31:909-913; *J.*
20 *Biol. Chem.* 1999;274:9116-9121; *Invest. Ophthalmol Vis. Sci.* 2000; 41:2309-2317). More recently, PPAR- γ agonists have been shown to inhibit the angiogenic response to VEGF in vitro; both troglitazone and rosiglitazone maleate inhibit the development of retinal neovascularization in mice. (*Arch. Ophthalmol.* 2001; 119:709-717).
Examples of PPAR- γ agonists and PPAR- γ/α agonists include, but are not limited to,
25 thiazolidinediones (such as DRF2725, CS-011, troglitazone, rosiglitazone, and pioglitazone), fenofibrate, gemfibrozil, clofibrate, GW2570, SB219994, AR-H039242, JTT-501, MCC-555, GW2331, GW409544, NN2344, KRP297, NP0110, DRF4158, NN622, GI262570, PNU182716, DRF552926, 2-[(5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy]-2-methylpropionic acid (disclosed in
30 USSN 09/782,856), and 2(R)-7-(3-(2-chloro-4-(4-fluorophenoxy) phenoxy)propoxy)-2-ethylchromane-2-carboxylic acid (disclosed in USSN 60/235,708 and 60/244,697).

- Another embodiment of the instant invention is the use of the presently disclosed compounds in combination with gene therapy for the treatment of cancer. For an overview of genetic strategies to treating cancer see Hall et al (*Am J Hum*
35 *Genet* 61:785-789, 1997) and Kufe et al (*Cancer Medicine*, 5th Ed, pp 876-889, BC Decker, Hamilton 2000). Gene therapy can be used to deliver any tumor suppressing gene. Examples of such genes include, but are not limited to, p53, which can be delivered via recombinant virus-mediated gene transfer (see U.S. Patent No. 6,069,134, for example), a uPA/uPAR antagonist ("Adenovirus-Mediated Delivery of

- 5 a uPA/uPAR Antagonist Suppresses Angiogenesis-Dependent Tumor Growth and Dissemination in Mice," Gene Therapy, August 1998;5(8):1105-13), and interferon gamma (J Immunol 2000;164:217-222).

10 When a composition according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.

15 In one exemplary application, a suitable amount of an inhibitor of one, two or all three of the Akt/PKB isoforms is administered to a mammal undergoing treatment for cancer. Administration occurs in an amount of inhibitor of between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day. A particular therapeutic dosage that comprises the instant composition includes from about 0.01mg to about 1000mg of inhibitor of Akt/PKB. Preferably, the dosage comprises from about 1mg to about 1000mg of inhibitor of Akt/PKB.

20 Examples of an antineoplastic agent include, in general, microtubule-stabilizing agents (such as paclitaxel (also known as Taxol®), docetaxel (also known as Taxotere®), or their derivatives); alkylating agents, anti-metabolites; epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; 25 mitoxantrone; platinum coordination complexes; biological response modifiers and growth inhibitors; hormonal/anti-hormonal therapeutic agents and hematopoietic growth factors.


30 Example classes of antineoplastic agents include, for example, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the taxanes, the epothilones, discodermolide, the pteridine family of drugs, diynenes and the podophyllotoxins. Particularly useful members of those classes include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, 35 podophyllotoxin or podo-phyllotoxin derivatives such as etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosine, vindesine, leurosine, paclitaxel and the like. Other useful antineoplastic agents include estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, gemcitabine, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabine, edatrexate,

- 5 trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins.

Compounds which are useful in the methods of treatment of the instant invention and are identified by the properties described hereinabove include:

10

- i) a compound of the formula I:



- 15 wherein

R^1 represents phenyl, furyl, thienyl or pyridinyl, any of which groups may be optionally substituted with one, two or three substituents, independently selected from:


- 20 a) halogen;
b) C_{1-4} alkyl;
c) C_{1-4} alkoxy;
d) cyano;
e) di(C_{1-4} alkyl)amino;
f) hydroxy;

- 25 R^2 represents amino- C_{1-6} alkyl, C_{1-4} alkylamino-(C_{1-6})alkyl, di(C_{1-4} alkyl)amino-(C_{1-6})alkyl, hydroxy-(C_{1-6})alkyl or C_{1-4} alkoxy-(C_{1-6})alkyl, any of which groups may be optionally substituted;

R^3 represents hydrogen or C_{1-6} alkyl; and

- 30 R^4 is selected from: C_{3-7} cycloalkyl and aryl, any of which groups may be optionally substituted;

- ii) a compound of the formula II:



5

wherein

R¹ represents phenyl, furyl, thienyl or pyridinyl, any of which groups may be optionally substituted with one, two or three substituents, independently selected from:

10


- a) halogen;
- b) C₁₋₄ alkyl;
- c) C₁₋₄ alkoxy;
- d) cyano;
- 15 e) di(C₁₋₄ alkyl)amino;
- f) hydroxy;

R² represents amino-C₁₋₆ alkyl, C₁₋₄ alkylamino-(C₁₋₆)alkyl, di(C₁₋₄ alkyl)amino-(C₁₋₆)alkyl, hydroxy-(C₁₋₆)alkyl or C₁₋₄ alkoxy-(C₁₋₆)alkyl, any of which groups may be optionally substituted; and

20

R⁴ is selected from: C₃₋₇ cycloalkyl and aryl, any of which groups may be optionally substituted;

iii) a compound of the formula III:



25

wherein

5 R^1 represents phenyl, furyl, thienyl or pyridinyl, any of which groups may be optionally substituted with one, two or three substituents, independently selected from:

- 10 a) halogen;
b) C_{1-4} alkyl;
c) C_{1-4} alkoxy;
d) cyano;
e) di(C_{1-4} alkyl)amino;
f) hydroxy;


15 R^2 represents amino- C_{1-6} alkyl, C_{1-4} alkylamino- (C_{1-6}) alkyl, di(C_{1-4} alkyl)amino- (C_{1-6}) alkyl, hydroxy- (C_{1-6}) alkyl or C_{1-4} alkoxy- (C_{1-6}) alkyl, any of which groups may be optionally substituted;

R^3 represents hydrogen or C_{1-6} alkyl; and

R^4 independently represents hydrogen, C_{1-6} -alkyl, halogen, HO- or C_{1-6} alkyl-O;

20 r is 1 or 2;

iv) a compound of the formula IV:



25

wherein

R^1 independently represents amino, C_{1-6} -alkyl amino, di- C_{1-6} -alkylamino, amino- C_{1-6} alkyl, C_{1-6} alkylamino- (C_{1-6}) alkyl or di(C_{1-6} alkyl)amino- (C_{1-6}) alkyl;

30

R^2 independently represents hydrogen, amino, C_{1-6} -alkyl amino, di- C_{1-6} -alkylamino, amino- C_{1-6} alkyl, C_{1-6} alkylamino- (C_{1-6}) alkyl or di(C_{1-6} alkyl)amino- (C_{1-6}) alkyl;


5

r is 1 to 3;

s is 1 to 3;

v) a compound of the formula V:

10



wherein

15 R¹ independently represents hydrogen, C₁₋₆-alkyl, halogen, HO- or C₁₋₆ alkyl-O;

or a pharmaceutically acceptable salt thereof.

20 As used herein, the expression "C₁₋₆ alkyl" includes methyl and ethyl groups, and straight-chained or branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, *n*-propyl, isopropyl, *tert*-butyl and 2,2-dimethylpropyl. Derived expressions such as "C₁₋₆ alkoxy" are to be construed accordingly.

25 As used herein, the expression "C₁₋₄ alkyl" includes methyl and ethyl groups, and straight-chained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl, *n*-propyl, isopropyl and *tert*-butyl. Derived expressions such as "C₁₋₄ alkoxy" are to be construed accordingly.

Typical C₃₋₇ cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

30 The expression "C₃₋₇ cycloalkyl(C₁₋₆)alkyl" as used herein includes cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl.

Typical C₄₋₇ cycloalkenyl groups include cyclobutenyl, cyclopentenyl and cyclohexenyl.

5 Typical aryl groups include phenyl and naphthyl, preferably phenyl.

The expression "aryl(C₁₋₆)alkyl" as used herein includes benzyl, phenylethyl, phenylpropyl and naphthylmethyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluorine or chlorine.

10 For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a
15 solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically
20 acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

The present invention includes within its scope prodrugs of the compounds of formulae I-V above. In general, such prodrugs will be functional
25 derivatives of the compounds of formulae I-V which are readily convertible *in vivo* into the required compound of formulae I-V. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in *Design of Prodrugs*, ed. H. Bundgaard, Elsevier, 1985.

Where the compounds useful in the instant methods of treatment have
30 at least one asymmetric center, they may accordingly exist as enantiomers. Where such compounds possess two or more asymmetric centers, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.

Examples of suitable values for the substituent R⁴ include methyl,
35 ethyl, isopropyl, *tert*-butyl, 1,1-dimethylpropyl, methyl-cyclopropyl, cyclobutyl, methyl-cyclobutyl, cyclopentyl, methyl-cyclopentyl, cyclohexyl, cyclobutenyl, phenyl, pyrrolidiny, methyl-pyrrolidiny, piperidiny, morpholiny, thiomorpholiny, pyridiny, furyl, thienyl, chloro-thienyl and diethylamino.

5 In a particular embodiment, the substituent R^4 represents C_{3-7} cycloalkyl or phenyl, either unsubstituted or substituted by C_{1-6} alkyl, especially methyl. Favourably, Z represents cyclobutyl or phenyl.

Examples of typical optional substituents on the group R^1 include methyl, fluoro and methoxy.


10 Representative values of R^1 include cyclopropyl, phenyl, methylphenyl, fluorophenyl, difluorophenyl, methoxyphenyl, furyl, thienyl, methylthienyl and pyridinyl.

In a particular embodiment, R^2 represents amino- C_{1-6} alkyl, C_{1-4} alkylamino- (C_{1-6}) alkyl or di(C_{1-4} alkyl)amino- (C_{1-6}) alkyl. Representative values of R^2 include but are not limited to dimethylaminomethyl, aminoethyl, dimethylaminoethyl, diethylaminoethyl, 3-dimethylaminopropyl, 3-methylaminopropyl, 3-dimethylamino-2,2-dimethylpropyl and , 3-dimethylamino-2-methylpropyl.

Suitably, R^3 represents hydrogen or methyl.

20 In a particular embodiment of the method of the instant invention, the compound that selectively inhibits one or two of the Akt/PKB isoforms is selected from:

i) a compound of the formula IA:



25

wherein


R^2 is as defined with reference to formula I above;

30 R^4 is selected from: C_{3-7} cycloalkyl and phenyl, any of which groups may be optionally substituted.

m is 0, 1, 2 or 3; and

R^5 independently represents halogen, C_{1-4} alkyl or C_{1-6} alkoxy;


- 5 ii) a compound of the formula IIA:



wherein

- 10 R^2 is as defined with reference to formula II above;
 R^4 is selected from: C_{3-7} cycloalkyl and phenyl, any of which groups
 may be optionally substituted.
 m is 0, 1, 2 or 3; and
 R^5 independently represents halogen, C_{1-4} alkyl or C_{1-6} alkoxy;

- 15 iii) a compound of the formula IVa:



20 wherein

R^1 independently represents amino, C_{1-6} -alkyl amino, di- C_{1-6} -alkylamino, amino- C_{1-6} alkyl, C_{1-6} alkylamino- (C_{1-6}) alkyl or di(C_{1-6} alkyl)amino- (C_{1-6}) alkyl;
 or the pharmaceutically acceptable salts thereof.

25

Specific compounds which are inhibitors of one or two of the Akt/PKB isoforms and are therefore useful in the present invention include:

- 5 N'-(7-Cyclobutyl-3-phenyl-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-2,2,*N,N*-tetramethyl-propane-1,3-diamine
- N'-(7-Cyclobutyl-3-(3,5-difluoro-phenyl)-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-2,2,*N,N*-tetramethyl-propane-1,3-diamine
- 10 N'-(7-Cyclobutyl-3-(3,4-difluoro-phenyl)-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-2,2,*N,N*-tetramethyl-propane-1,3-diamine
- 15 N'-(7-Cyclobutyl-3-(4-fluoro-phenyl)-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-2,2,*N,N*-tetramethyl-propane-1,3-diamine
- N'-(7-Cyclobutyl-3-(3-fluoro-phenyl)-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-2,2,*N,N*-tetramethyl-propane-1,3-diamine
- 20 2,2,*N,N*-tetramethyl-*N*-(3-phenyl-[1,2,4]triazolo[3,4-*a*]phthalazin-6-yl)-propane-1,3-diamine
- N'-(3-(4-Methoxy-phenyl)-[1,2,4]triazolo[4,3-*a*]phthalazin-6-yl)-2,2,*N,N*-tetramethyl-propane-1,3-diamine
- 25 6-(2-hydroxyethyl)oxy-3,7-diphenyl-[1,2,4]triazolo[4,3-*b*]pyridazine
- 6-(4-hydroxybutyl)oxy-3,7-diphenyl-[1,2,4]triazolo[4,3-*b*]pyridazine
- 30 2-(2-aminoprop-2-ylphenyl)-3-phenylquinazoline
- 1-{1-[4-(7-Phenyl-1*H*-imidazo[4,5-*g*]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2*H*-benzimidazol-2-one
- 35 1-{1-[4-(6-Hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2*H*-benzimidazol-2-one

- 5 1-{1-[4-(5-Hydroxy-6-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
- 1-(1-{4-[5-Hydroxy-6-(1H-indol-3-ylmethyl)-3-phenylpyrazin-2-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one
- 10 1-(1-{4-[6-Hydroxy-5-(1H-indol-3-ylmethyl)-3-phenylpyrazin-2-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one
- 15 1-{1-[4-(3-Phenylquinoxalin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
- 3-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzamidazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylquinaxoline-6-carboxylic acid
- 20 2-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzamidazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylquinaxoline-6-carboxylic acid
- N-[3-(1H-Imidazol-1-yl)propyl]-3-(4-{[4-(2-oxo-2,3-dihydro-1H-benzamidazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylquinaxoline-6-carboxamide
- 25 1-{1-[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
- 1-{1-[4-(2-phenylpyrido[3,4-b]pyrazin-3-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
- 30

or the pharmaceutically acceptable salt thereof.

- 35 All patents, publications and pending patent applications identified are hereby incorporated by reference.

The compounds used in the present method may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. Unless otherwise specified, named amino acids are understood to have

5 the natural "L" stereoconfiguration

The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.

Abbreviations used in the description of the chemistry and in the Examples that follow are:

15	Ac ₂ O	acetic anhydride;
	Boc	t-butoxycarbonyl;
	DBU	1,8-diazabicyclo[5.4.0]undec-7-ene;
	TFA:	trifluoroacetic acid
	AA:	acetic acid
20	4-Hyp	4-hydroxyproline
	Boc/BOC	t-butoxycarbonyl;
	Chg	cyclohexylglycine
	DMA	dimethylacetamide
	DMF	dimethylformamide;
25	DMSO	dimethyl sulfoxide;
		1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride;
	EtOAc	ethyl acetate;
	EtOH	ethanol;
	FAB	Fast atom bombardment;
30	HOAt	1-hydroxy-7-azabenzotriazole
	HOBt	1-hydroxybenzotriazole hydrate;
	HOPO	2-hydroxypyridine-N-oxide
	HPLC	High-performance liquid chromatography;
	IPAc	isopropylacetate
35	MeOH	methanol
	RPLC	Reverse Phase Liquid Chromatography
	THF	tetrahydrofuran.
	DCE	dichloroethane
	DCM	dichloromethane

- 5 n-Pr n-propyl
 PS-NMM polystyrene N-methylmorpholine
 TFA trifluoroacetic acid
 MP-CNBH₃ macroporous cyanoborohydride;
 PS-DCC polystyrene-dicyclohexyl carbodiimide;
 10 PS-DIEA polystyrene diisopropylethylamine;

Reactions used to generate the compounds which are inhibitors of Akt activity and are therefore useful in the methods of treatment of this invention are shown in the Schemes 1-6, in addition to other standard manipulations such as ester
 15 hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Substituents R and R^a, as shown in the Schemes, represent the substituents R¹ and R²; however their point of attachment to the ring is illustrative only and is not meant to be limiting.

These reactions may be employed in a linear sequence to provide the
 20 compounds of the invention or they may be used to synthesize fragments that are subsequently joined by the alkylation reactions described in the Schemes.

SYNOPSIS OF SCHEMES 1-6:

The requisite intermediates are in some cases commercially available,
 25 or can be prepared according to literature procedures. As illustrated in Reaction Scheme 1, a suitably substituted phenylmaleic anhydride i is treated with hydrazine to form the dihydropyridazone dione ii. Subsequent oxidative chlorination and reaction with a suitably substituted benzoic hydrazide provide the 6-chloro triazolo [4,3-*b*]pyridazine iii. This intermediate can then be treated with a variety of alcohols and
 30 amines to provide the compound iv.

Reaction Scheme 2 illustrates preparation of compounds useful in the methods of the instant invention having a cycloalkyl substituent at the 7-position. While a cyclobutyl group is illustrated, the sequence of reactions is generally applicable to incorporation of a variety of unsubstituted or substituted cycloalkyl
 35 moieties. Thus, 3,6-dichloropyridazine is alkylated via silver catalyzed oxidative decarboxylation with cyclobutyl carboxylic acid to provide the cyclobutyl dichloropyridazine v, which then undergoes the reactions described above to provide the instant compound vi.

5 Reaction Scheme 3 illustrates the same reaction sequence used to prepare compounds of the Formula I


Reaction Scheme 4 illustrates an alternative preparation of the instant compounds (*Tetrahedron Letters* 41:781-784 (2000)).

10 Reaction Scheme 5 illustrates a synthetic method of preparing the compounds of the Formula IV hereinabove.


Reaction Scheme 6 illustrates a synthetic method of preparing the compounds of the Formula III hereinabove.

Reaction Scheme 1




15




5

Reaction Scheme 2


10

Reaction Scheme 3





5

Reaction Scheme 4

5


Reaction Scheme 4 (continued)

5

Reaction Scheme 5

208040" 2804E09

5

Reaction Scheme 6EXAMPLES

10

Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof.

15

EXAMPLE 1

N'-(7-Cyclobutyl-3-phenyl-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-2,2,*N,N*-tetramethylpropane-1,3-diamine (Compound 1)

20

5 Step 1: 3,6-Dichloro-4-cyclobutylpyridazine

Concentrated sulphuric acid (53.6 ml, 1.0 mol) was added carefully to a stirred suspension of 3,6-dichloropyridazine (50.0 g, 0.34 mol) in water (1.25 l). This mixture was then heated to 70°C (internal temperature) before the addition of cyclobutane carboxylic acid (35.3 ml, 0.37 mol). A solution of silver nitrate (11.4 g, 0.07 mol) in water (20ml) was then added over approximately one minute. This caused the reaction mixture to become milky in appearance. A solution of ammonium persulphate (230 g, 1.0 mol) in water (0.63 l) was then added over 20-30 minutes. The internal temperature rose to approximately 85°C. During the addition the product formed as a sticky precipitate. Upon complete addition the reaction was stirred for an additional 5 minutes, then allowed to cool to room temperature. The mixture was then poured onto ice and basified with concentrated aqueous ammonia, with the addition of more ice as required to keep the temperature below 10°C. The aqueous phase was extracted with dichloromethane (x3). The combined extracts were dried (MgSO₄), filtered and evaporated to give the title compound (55.7 g, 82%) as an oil. ¹H nmr (CDCl₃) indicated contamination with approximately 5% of the 4,5-dicyclobutyl compound. However, this material was used without further purification. Data for the title compound: ¹H NMR (360 MHz, d₆-DMSO) δ 1.79-1.90 (1H, m), 2.00-2.09 (1H, m), 2.18-2.30 (2H, m), 2.33-2.40 (2H, m), 3.63-3.72 (1H, m), 7.95 (1H, s); MS (ES⁺) m/e 203 [MH]⁺, 205 [MH]⁺, 207 [MH]⁺.

25 Step 2: 6-Chloro-7-cyclobutyl-3-phenyl-1,2,4-triazolo[4,3-b]pyridazine

A mixture of 3,6-dichloro-4-cyclobutylpyridazine from above (55.7 g, 0.27 mol), benzoic hydrazide (41.1 g, 0.30 mol) and triethylamine hydrochloride (41.5 g, 0.30 mol) in *p*-xylene (0.4 l) was stirred and heated at reflux under a stream of nitrogen for 24 hours. Upon cooling the volatiles were removed *in vacuo*. The residue was partitioned between dichloromethane and water. The aqueous layer was basified by the addition of solid potassium carbonate. Some dark insoluble material was removed by filtration at this stage. The aqueous phase was further extracted with dichloromethane (x2). The combined extracts were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography on silica gel eluting with 5%→10%→25% ethyl acetate/dichloromethane to give the title compound, (26.4 g, 34%) as an off-white solid. Data for the title compound: ¹H NMR (360 MHz, CDCl₃) δ 1.90-2.00 (1H, m), 2.12-2.28 (3H, m), 2.48-2.57 (2H, m), 3.69-3.78 (1H, m), 7.49-7.59 (3H, m), 7.97 (1H, s), 8.45-8.48 (2H, m); MS (ES⁺) m/e 285 [MH]⁺, 287 [MH]⁺.

- 5 Step 3: N'-(7-Cyclobutyl-3-phenyl-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-
2,2,*N,N*-tetramethyl-propane-1,3-diamine
6-Chloro-7-cyclobutyl-3-phenyl-[1,2,4]triazolo[4,3-*b*]pyridazine
(100mg) and *N,N*,2,2-tetramethyl-1,3-propanediamine (2ml) were heated together in
a sealed tube at 70°C for 16 hours. Cooled and water (5ml) added. Precipitate filtered,
10 washed (water, ether) and dried. ¹H NMR (250MHz, DMSO) δ 1.20 (6H, s), 2.10
(1H, m), 2.24-2.65 (14H, m), 3.53-3.70 (2H, m), 7.69-7.82 (4H, m), 8.03 (1H, s), 8.70
(2H, m). MS (ES+) MH⁺ = 379

EXAMPLE 2

- 15 N'-(7-Cyclobutyl-3-(3,5-difluoro-phenyl)-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-
2,2,*N,N*-tetramethyl-propane-1,3-diamine (Compound 2)
The title compound was prepared in an analogous fashion to Example
1, except substituting 3,5-difluorobenzoic hydrazine for the benzoic hydrazine in Step
20 2. ¹H NMR (360MHz, CDCl₃) δ 1.07 (6H, s), 1.99 (1H, m), 2.10-2.50 (13H, m), 3.31-
3.35 (3H, m), 6.84-6.89 (1H, m), 7.63 (1H, s), 7.90 (1H, vbs), 8.20-8.23 (2H, m). MS
(ES+) MH⁺ = 415

EXAMPLE 3

- 25 N'-(7-Cyclobutyl-3-(3,4-difluoro-phenyl)-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-
2,2,*N,N*-tetramethyl-propane-1,3-diamine (Compound 3)
The title compound was prepared in an analogous fashion to Example
1, except substituting 3,4-difluorobenzoic hydrazine for the benzoic hydrazine in Step
30 2. ¹H NMR (360MHz, CDCl₃) δ 1.07 (6H, s), 1.99-2.49 (14H, m), 3.30-3.33 (3H, m),
7.25-7.30 (1H, m), 7.62 (1H, s), 7.87 (1H, vbs), 8.32-8.34 (1H, m), 8.51-8.57 (1H, m).
MS (ES+) MH⁺ = 415

5

EXAMPLE 4

N'-(7-Cyclobutyl-3-(4-fluoro-phenyl)-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-2,2,*N,N*-tetramethyl-propane-1,3-diamine (Compound 4)

10 The title compound was prepared in an analogous fashion to Example 1, except substituting 4-fluorobenzoic hydrazine for the benzoic hydrazine in Step 2. ¹H NMR (360MHz, CDCl₃) δ 1.06 (6H, s), 1.98-2.49 (14H, m), 3.31-3.32 (3H, m), 7.18-7.26 (2H, m), 7.61 (1H, s), 7.80 (1H, vbs), 8.55-8.59 (2H, m). MS (ES+) MH⁺ = 397

EXAMPLE 5

15

N'-(7-Cyclobutyl-3-(3-fluoro-phenyl)-[1,2,4]triazolo[4,3-*b*]pyridazin-6-yl)-2,2,*N,N*-tetramethyl-propane-1,3-diamine (Compound 5)

20 The title compound was prepared in an analogous fashion to Example 1, except substituting 3-fluorobenzoic hydrazine for the benzoic hydrazine in Step 2. ¹H NMR (360MHz, CDCl₃) δ 1.07 (6H, s), 1.96-2.50 (14H, m), 3.31-3.35 (3H, m), 7.10-7.15 (1H, m), 7.44-7.50 (1H, m), 7.63 (1H, m) 7.81 (1H, vbs), 8.35-8.42 (2H, m). MS (ES+) MH⁺ = 397

EXAMPLE 6

25

2,2,*N,N*-tetramethyl-*N*-(3-phenyl-[1,2,4]triazolo[3,4-*a*]phthalazin-6-yl)-propane-1,3-diamine (Compound 6)

Step 1: 1-Chloro-4-hydrazinophthalazine hydrochloride

30

To a stirred solution of hydrazine hydrate (40ml) in ethanol (120ml) at 80°C was added 1,4-dichlorophthalazine (20g). This reaction mixture was stirred at 80°C for 0.5 hours, then left to cool and the product was collected by filtration and dried under vacuum to give 1-chloro-4-hydrazinophthalazine hydrochloride (14.6g). ¹H NMR (250 MHz, DMSO) δ 4.64 (2H, vbs), 7.2 (1H, vbs), 7.92 (4H, bm).

35

Step 2: 6-Chloro-3phenyl-1,2,4-triazolo[3,4-*a*]phthalazine

To a solution of 1-chloro-4-hydrazinophthalazine hydrochloride (10g) in dioxan (220ml) was added triethylamine (7.24ml) and benzoyl chloride (6.04ml).

5 This mixture was heated at reflux for 8 hours under nitrogen. After cooling the reaction mixture was concentrated under vacuum and the solid obtained was collected by filtration, washed with water and diethyl ether and dried under vacuum, to yield the title compound (12.0g). ¹H NMR (250 MHz, DMSO) δ 7.60 (3H, m), 8.00 (1H, t, J=8.4Hz), 8.19 (1H, t, J=8.4Hz), 8.31 (3H, m), 8.61 (1H, d, J=6.3Hz).

10

Step 3: 2,2,N,N-tetramethyl-N-(3-phenyl-[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-propane-1,3-diamine

The title compound was prepared as described in Example 1, Step 3, but replacing the 6-Chloro-7-cyclobutyl-3-phenyl-[1,2,4]triazolo[4,3-b]pyridazine with the 6-Chloro-3-phenyl-1,2,4-triazolo[3,4-a]phthalazine from Step 2. ¹H NMR (360MHz, CDCl₃) δ 1.13 (6H, s), 2.35 (2H, s), 2.46-2.50 (8H, m), 3.47 (2H, vbs), 7.16-7.27 (2H, m), 7.44-7.86 (5H, m), 8.55-8.57 (2H, m), 8.68 (1H, m). MS (ES+) MH⁺ = 375

20

EXAMPLE 7

N'-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[4,3-a]phthalazin-6-yl]-2,2,N,N-tetramethylpropane-1,3-diamine (Compound 7)

The title compound was prepared in an analogous fashion to Example 1, except substituting 3-fluorobenzoic hydrazine for the benzoic hydrazine in Step 2. ¹H NMR (360MHz, CDCl₃) δ 1.13 (6H, s), 2.45 (6H, s), 2.49 (2H, s), 3.45-3.46 (2H, m), 3.90 (3H, s) 7.04-7.07 (2H, m), 7.65-7.70 (2H, m), 7.80-7.84 (1H, m), 8.51 (2H, m), 8.66 (1H, m). MS (ES+) MH⁺ = 405

30

EXAMPLE 8

6-(2-Hydroxyethyl)oxy-3,7-diphenyl-[1,2,4]triazolo[4,3-b]pyridazine (Compound 8)

Step 1: 4-Phenyl-1,2-dihydropyridazine-3,6-dione

Phenylmaleic anhydride (30 g, 0.17 mol), sodium acetate trihydrate (28 g, 0.21 mol) and hydrazine monohydrate (10 ml, 0.21 mol) were heated together at reflux in 40% acetic acid (600 ml) for 18 hours. The mixture was cooled at 7°C for 2 hours, then filtered. The solid was washed with diethyl ether and dried *in vacuo* to give 11 g (34%) of the title compound: ¹H NMR (250 MHz, DMSO-d₆) δ 7.16 (1H, br s), 7.44 (5H, m), 7.80 (2H, br s); MS (ES⁺) m/e 189 [MH⁺].

5

Step 2: 3,6 Dichloro-4-phenylpyridazine

4-Phenyl-1,2-dihydropyridazine-3,6-dione (3.4 g, 18 mmol) was heated at reflux in phosphorus oxychloride (70 ml) for 6 hours. The solution was concentrated *in vacuo*, then the residue was dissolved in dichloromethane (100 ml) and was neutralized by the addition of cold 10% aqueous sodium hydrogen carbonate (150 ml). The aqueous phase was washed with dichloromethane (2 x 50 ml), then the combined organic layers were washed with saturated aqueous sodium chloride (50 ml), dried (Na₂SO₄), and concentrated *in vacuo* to yield 3.9 g (97%) of the title compound: ¹H NMR (250 MHz, DMSO- *d*₆) δ 7.54-7.66 (5H, m) 8.14 (1H, s); MS (ES⁺) *m/e* 225/227/229 [MH⁺].

Step 3: 6-Chloro-3,7-diphenyl-1,2,3-trizolo[4,3-*b*]pyridazine

3,6-Dichloro-4-phenylpyridazine (2.9 g, 13 mmol), benzoic hydrazide (1.9 g, 21 mmol) and triethylammonium chloride (2.0 g, 14 mmol) were heated together at reflux in xylene (150 ml) for three days. More benzoic hydrazide (0.88 g, 6.5 mmol) was added and the mixture was heated as before for another day. The solvent was removed *in vacuo*, and the residue was purified by flash chromatography (silica gel, 0-50% EtAOc/CH₂Cl₂) to afford 1.4 g (36%) of the title compound as a solid: ¹H NMR (250 MHz, CDCl₃) δ 7.55 (8H, m), 8.12 (1H, s), 8.50 (2H, m); MS (ES⁺) *m/e* 307/309 [MH⁺].

Step 4: 6-(2-Hydroxyethyl)oxy-3,7-diphenyl-1,2,3-trizolo[4,3-*b*]pyridazine


Anhydrous DMF (1.5 ml) was added to a test tube containing NaH (13 mg) under nitrogen. Ethylene glycol (2 ml) was added and the mixture stirred at room temperature for 1 hour. The 6-chloro-3,7-diphenyl-1,2,3-trizolo[4,3-*b*]pyridazine (50 mg) (prepared as described in Step 3) was added as a solid and the reaction stirred at room temperature for 30 minutes and then heated at 60°C for 8 hours and then stirred 10 hours at room temperature. The reaction mixture was then poured over 20 ml of hot water, the mixture cooled and the aqueous mixture extracted with ether. The organic phases were combined, washed with water, dried over MgSO₄, filtered and concentrated under vacuum to provide the title compound. ¹H NMR (CDCl₃, 500 MHz at 20°C) δ 8.48 (d, 2H, *J* = 8.3), 8.04 (d, 1H, *J* = 0.7), 7.61 (m, 2H), 7.57 (dd, 2H, *J* = 7.6 and 8.1), 7.52 (m, 4H), 4.62 (dd, 2H, *J* = 3.9 and 5.1), 4.04 (d, 2H, *J* = 3.7). LC/MS (ES⁺) [M+1]⁺ = 333.2.

5

EXAMPLE 96-(2-Hydroxybutyl)oxy-3,7-diphenyl-[1,2,4]triazolo[4,3-*b*]pyridazine (Compound 9)

- The title compound was prepared by the procedure described in Example 1, but replacing ethylene glycol with 1,4-butanediol in Step 4. ¹H NMR (CDCl₃, 500 MHz at 20°C) δ 8.52 (dd, 2H, *J* = 7.8 and 1.5), 8.02 (d, 1H, *J* = 0.5), 7.58 (m, 4H), 7.51 (m, 4H), 4.53 (t, 2H, *J* = 6.4), 3.69 (app. t, 2H, *J* = 5.5), 1.97 (m 2H), 1.72 (m, 2H). LC/MS (ES+) [M+1] = 361.3.

15

EXAMPLE 10Preparation of 2-(2-aminoprop-2-ylphenyl)-3-phenylquinazoline (Compound 10)

20 Step 1: Preparation of Ethyl 4-iodobenzoate

- A mixture of 21.0 g of 4-iodobenzoic acid, 100ml of absolute EtOH and 6 ml of concentrated sulfuric acid was refluxed with stirring for 6 days. At the end of this time the reaction mixture was concentrated by boiling and an additional 4 ml of concentrated sulfuric acid added. The mixture was then refluxed for an additional 11 days, after which the mixture was cooled and 50 g of ice and 150 ml Et₂O were added. The phases were separated and the aqueous layer was extracted with Et₂O. The combined organic phases were washed with water, sat. aqueous NaHCO₃ and water. The organic phase was then dried over MgSO₄ and concentrated under vacuum to provide the title compound as a clear brownish liquid.

30

Step 2: Preparation of α,α-dimethyl-4-iodobenzyl alcohol

- 5 To a cooled (ice/H₂O) solution of 2.76 g of ethyl 4-iodobenzoate (prepared as described in Step 1) in 10 ml of anhyd. Et₂O was added, over a 5 minute period, 26.5ml of 1.52M CH₃MgBr/ Et₂O solution. The mixture was stirred at ice bath temperature for 2.5 hours and then quenched by slow addition of 6 ml of H₂O. The reaction mixture was filtered and the solid residue rinsed with ether. The
10 combined filtrates were dried over MgSO₄ and concentrated under vacuum to provide the title compound as a clear yellowish liquid.

Step 3: Preparation of α,α -dimethyl-4-iodo-N-formamido-benzyl amine

- 15 19 ml of glacial acetic acid was cooled in an ice bath until a slurry formed. 4.18g of sodium cyanide was added over a 30 minute period. A cooled (ice/H₂O) solution of 10.3 ml conc. sulfuric acid in 95 ml glacial acetic acid was added to the cyanide solution over a 15 min. period. The ice bath was removed and 19.92 g of the α,α -dimethyl-4-iodobenzyl alcohol (prepared as described in Step 2) was added over a 10 minute period. The resulting white suspension was stirred 90
20 minutes. And left standing overnight at room temperature. The reaction mixture was poured over ice and water and ether added. This mixture was neutralized with solid Na₂CO₃.

Step 4: Preparation of Copper (I) phenylacetylide

- 25 To a solution of 10.7 g of phenylacetylene in 500 ml of absolute ethanol was added a solution of 20 g of copper iodide in 250 ml of conc. NH₄OH and 100 ml of water. The solution was stirred 30 minutes and then filtered. The solid that was collected was washed with water, 95% aq. Ethanol and then ether. The solid was then collected and dried under vacuum to provide the title compound as a bright
30 yellow solid.

Step 5: Preparation of 1-(2-formamidoprop-2-ylphenyl)-2-phenylacetylene

- 35 A mixture of 11.83 g of the iodophenyl compound described in Step 3, 6.74 g of Copper (I) phenylacetylide and 165 ml of dry pyridine was stirred at 120°C for 72 hours. The reaction was then allowed to cool and the mixture was poured over approximately 300 g of ice and water with vigorous stirring. The mixture was then extracted with 1:1 benzene:diethylether. The organic solution was washed with 3N hydrochloric acid, dried over MgSO₄, filtered and concentrated to provide a solid, that was recrystallized from benzene/cyclohexane to provide the title compound.

5

Step 6: Preparation of 4-(2-formamidoprop-2-yl)-benzil

1-(2-formamidoprop-2-ylphenyl)-2-phenylacetylene from Step 5 (4.81 g) was dissolved in 30 ml of dried DMSO. N-Bromosuccinamide (NBS) (5.65 g) was added and the reaction stirred at room temperature for 96 hours. At this time 500 mg of NBS was added and the reaction stirred an additional 24 hours. The reaction mixture was then poured over water and the aqueous mixture extracted with benzene. The combined organic phases were washed with water and dried over MgSO_4 . The organic slurry was then filtered and concentrated *in vacuo* to provide the title compound

15

Step 7: Preparation of 4-(2-aminoprop-2-yl)-benzil

4-(2-formamidoprop-2-yl)-benzil, prepared as described in Step 6 (6.17 g) was dissolved in 100 ml of glacial acetic acid, 84 ml of water and 6 ml of concentrated HCl. The mixture was stirred at reflux for 3 hours and then the solvent removed under vacuum at 60°C. The residue was converted to the free based form, extracted with organic solvent, washed with water, dried and concentrated to provide the title compound as an oil.

20

Step 8: Preparation of 2-(2-aminoprop-2-ylphenyl)-3-phenylquinazoline

A mixture of 1.0 g of 4-(2-aminoprop-2-yl)-benzil from Step 7, 0.406 g of o-phenylenediamine, 25 ml of glacial acetic acid and 15 ml of water was refluxed for 4.5 hours. The mixture was then allowed to stand overnight at room temperature. Most of the solvent was then removed under vacuum and the residue was taken up in 30 ml of water and 50 ml of 6 N aq. NaOH was added. The gum that precipitated was extracted with chloroform. The organic solution was washed with water, dried over MgSO_4 and concentrated under vacuum.

25

30

The residue was redissolved in chloroform and ethanolic HCl was added, precipitating out the hydrochloride salt. The salt was recrystallized from *i*-PrOH to provide the title compound as the hydrochloride salt - *i*-PrOH solvate (pale yellow plates). Mp 269°C-271°C (melted/resolidified at 250°C).
Anal. Calc. for $\text{C}_{23}\text{H}_{21}\text{N}_3 \cdot \text{HCl} \cdot i\text{-PrOH}$:


35

C, 71.62; H, 6.94; N, 9.64.

Found: C, 71.93; H, 6.97; N, 9.72

- 5 ¹H NMR (CDCl₃, 500 MHz at 20°C) δ 9.04 (broad s, 2.4H), 8.10 (d, 1H, *J* = 7.8), 8.02 (d, 1H, *J* = 7.8), 7.72 (dd, 1H, *J* = 7.0 and 8.2), 7.66 (dd, 1H, *J* = 7.0 and 8.2), 7.56 (m, 4H), 7.46 (dd, 2H, *J* = 1.2 and 8.5), 7.31 (m, 3H), 1.81 (s, 6H). LC/MS (ES+) [M+1] = 340.3.

10

EXAMPLE 11Preparation of 2,3-bis(4-aminophenyl)-quinoxaline (Compound 11)

15

Step 1: Preparation of meso (d,l) hydrobenzoin

- To a slurry of 97.0 g of benzil in 1 liter of 95% EtOH was added 20 g of sodium borohydride. After stirring 10 minutes, the mixture was diluted with 1 liter of water and the mixture was treated with activated carbon. The mixture was then
 20 filtered through supercel and the filtrate heated and diluted with an additional 2 liters of water until it became slightly cloudy. The mixture was then cooled to 0 to 5°C and the resulting crystals were collected and washed with cold water. The crystals were then dried *in vacuo*.

25 Step 2: Preparation of 4,4'-dinitrobenzil

- 150 ml of fuming nitric acid was cooled to -10°C and 25 g of the hydrobenzoin (prepared as described in Step 1) was added slowly portionwise while maintaining the temperature between -10°C to -5°C. The reaction mixture was main-
 30 tained at 0°C for an additional 2 hours. 70 ml of water was added and the mixture was refluxed for 30 minutes and then poured onto 500 g of cracked ice. The residue was separated from the mixture by decantation and the residue was then boiled with 500 ml of water. The water layer was removed.

5 The remaining gum was dissolved in boiling acetone and the solution treated with decolorizing carbon and filtered. The filtrate was then cooled to -5°C and the resulting crystals were collected and washed with cold acetone and dried *in vacuo*. An additional crop of crystalline title compound was obtained from recrystallization of the mother liquor residue.

10

Step 2: Preparation of 4,4'-diaminobenzil

3.8 g of 4,4'-dinitrobenzil was reduced under hydrogen with 3.8g 10% Ru on C in EtOH. The mixture was filtered through Supracel and the filtrate concentrated under vacuum to dryness. The residue was dissolved in 50% denatured ethanol in water, treated with Darco and filtered. The filtrate was cooled to 0°C and the resulting crystals were collected and washed with 50% denatured ethanol in water. The crystals were then dried under a heat lamp to give the title compound as a yellow powder.

20

Step 3: Preparation of 2,3-bis(4-aminophenyl)-quinoxaline

A mixture of 1.0 g (4.17 mmole) of 4,4'-diaminobenzil and 0.45 g of o-phenylenediamine in 250 ml glacial acetic acid was heated at 50°C for 15 minutes, then stirred for 16 hours at room temperature. The mixture was then heated to 80°C and allowed to cool slowly. The solvent was removed under vacuum and the residue was redissolved in ethanol and that was removed under vacuum.

25

The solid residue was recrystallized from boiling acetone, and the solid collected. The residue from the mother liquors was recrystallized from 95% EtOH and the resulting crystals combined with the crystals from the acetone crystallization and all were recrystallized from 1:1 abs. EtOH:95% EtOH to provide crystalline material.

30

The crystals were dried for over 5 hours at 110°C under vacuum to provide the title compound.

Anal. Calc. for C₂₀H₁₆N₄ :

C, 76.90; H, 5.16; N, 17.94.


Found: C, 76.83; H, 4.88; N, 18.16

35

¹H NMR (CDCl₃, 500 MHz at 20°C) δ 8.08 (m, 2H), 7.67 (m, 2H), 7.39 (m, 4H), 6.64 (m, 4H), 3.80 (broad s, 4H).

5 LC/MS (ES+) [M+1]= 313.3.

EXAMPLE 12



10

Step 1: 1-(4-{{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylethane-1,2-dione 12-3

To an 8 mL vial was placed bromomethyl benzil 12-2 (Toronto Research chemicals, 500 mg, 1.65 mmol), 4-(2-keto-1-benzimidazol-1-yl)piperidine (Aldrich, 358 mg, 1.65 mol), PS-DIEA (887 mg, 3.3 mmol, 3.72 mmol/g) and dry THF (6 mL, 0.3 M). The vial was placed on a GlasCol rotator and allowed to rotate for 2 hours. After this time, the contents of the vial were filtered through a 10 mL BioRad

15



5 tube, washed with THF and concentrated in vacuo. The crude material was then purified on an Agilent 1100 series Mass Guided HPLC purification system to afford the TFA salt of 12-3 as a pale yellow solid. Analytical LCMS: single peak (214 nm) at 2.487 min (CH₃CN/H₂O/1%TFA, 4 min gradient). ¹H NMR (500 MHz, DMSO-*d*₆): δ 10.9 (s, 1H), 8.05 (m, 2H), 7.93 (m, 2H), 7.79 (m, 2H), 7.63 (m, 2H), 7.24 (s, 1H),
 10 6.98 (s, 4H), 4.47 ((s, 2H), 3.5 (m, 2H), 3.2 (m, 3H), 2.61 (q, *J*=11 Hz, 2H), 1.9 (d, *J*=11 Hz, 2H). HRMS, calc'd for C₂₇H₂₆N₃O₃ (M+H), 440.1965; found 440.1968.

Step 2: 1-{1-[4-(7-Phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one 12-5

15 To an 8 mL vial was placed 1-(4-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)pipepridin-1-yl]methyl}phenyl)-2-phenylethane-1,2-dione 12-3 (56 mg, 0.10 mmol), 5,6-diaminobenzimidazole, trihydrochloride 12-4 (25 mg, 0.10 mol) and dissolved in EtOH (2 mL). The vial was placed in a J-KEM heater/shaker block and warmed to 90 degrees for 9 hours. After this time, the vials were cooled
 20 and concentrated in vacuo. The crude material was then purified on an Agilent 1100 series Mass Guided HPLC purification system to afford of the TFA salt of 12-5 as a brown solid. Analytical LCMS: single peak (214 nm) at 2.066 min (CH₃CN/H₂O/1%TFA, 4 min gradient). ¹H NMR (600 MHz, CD₃OD): δ 9.32 (s, 1H), 8.52 (s, 2H), 7.71 (d, *J*=8.1 Hz, 1H), 7.58 (d, *J*=8.1 Hz, 2H), 7.55 (d, *J*=7.7 Hz, 2H),
 25 7.43 (t, *J*=7.0 Hz, 1H) 7.38 (t, *J*=7.0 Hz, 2H), 7.28 (m, 1H), 7.07 (m, 3H), 4.59 (m, 1H), 4.43 (s, 2H), 3.66 (d, *J*=12.1 Hz, 2H), 3.28 (t, *J*=12.0 Hz, 2H), 2.82 (q, *J*=11.8 Hz, 2H), 2.08 (d, *J*=13.9 Hz, 2H). HRMS, calc'd for C₃₄H₂₉N₇O (M+H), 552.2503; found 552.2503.




30 Compounds in Table 1 were synthesized as shown in Example, but substituting the appropriately substituted cyclic amine for compound 12-2 in the example: The TFA salt of the compound shown was isolated by Mass Guided HPLC purification.

5 Table 1


#	Compound	MS M+1
12-6		536.6
12-7		536.6

208040-2280209

5

EXAMPLE 13

13-4



13-5

5 Step 1: 1-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)pipepridin-1-yl]methyl}phenyl)-2-phenylethane-1,2-dione 13-3

To an 8 mL vial was placed bromomethyl benzil 13-1 (Toronto Research Chemicals, 500 mg, 1.65 mmol), 4-(2-keto-1-benzimidazoliny)l)piperidine 13-2 (Aldrich, 358 mg, 1.65 mol), PS-DIEA (887 mg, 3.3 mmol, 3.72 mmol/g) and dry
 10 THF (6 mL, 0.3 M). The vial was placed on a GlasCol rotator and allowed to rotate for 2 hours. After this time, the contents of the vial were filtered through a 10 mL BioRad tube, washed with THF and concentrated in vacuo. The crude material was then purified on an Agilent 1100 series Mass Guided HPLC purification system to afford the TFA salt of 13-3 as a pale yellow solid. Analytical LCMS: single peak
 15 (214 nm) at 2.487 min (CH₃CN/H₂O/1%TFA, 4 min gradient). ¹H NMR (500 MHz, DMSO-*d*₆): δ 10.9 (s, 1H), 8.05 (m, 2H), 7.93 (m, 2H), 7.79 (m, 2H), 7.63 (m, 2H), 7.24 (s, 1H), 6.98 (s, 4H), 4.47 ((s, 2H), 3.5 (m, 2H), 3.2 (m, 3H), 2.61 (q, *J*=11 Hz, 2H), 1.9 (d, *J*=11 Hz, 2H). HRMS, calc'd for C₂₇H₂₆N₃O₃ (M+H), 440.1965; found 440.1968.

20 Step 2: 1-{1-[4-(6-Hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one 13-4 and 1-{1-[4-(5-Hydroxy-6-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one 13-5




25 1-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)pipepridin-1-yl]methyl}phenyl)-2-phenylethane-1,2-dione 13-3 (1.661 g, 30 mmol), leucine carboxamide HCl (0.501 g, 3.0 mmol), and K₂CO₃ (0.829 g, 6.0 mmol) were dissolved in 30 mL of EtOH/H₂O (5/1) in a one-necked, 100 ML flask. The mixture solution is heated at 90 °C for 16 hours. After this time, the reaction were cooled and
 30 concentrated in vacuo. The crude material was then purified on an Agilent 1100 series Mass Guided HPLC purification system to afford the TFA salts of 13-4 and 13-5 as slightly yellow solids.

13-4: Analytical LCMS: single peak (214 nm) at 2.655min (CH₃CN/H₂O/1%TFA, 4 min gradient). ¹H NMR (500 MHz, CD₃OD): δ 7.54 (d, *J*=7.9 Hz, 2H), 7.47 (d, *J*=7.7 Hz, 2H), 7.24 (m, 6H) 7.08 (d, *J*=2.4 Hz, 3H), 4.57 (m, 1H), 4.40 (s, 2H), 3.63 (d, *J*=11.5 Hz, 2H), 3.26 (t, *J*=12.6 Hz, 2H), 2.78 (m, 4H), 2.29 (m., 2H) 2.09 (d, *J*=12.8 Hz, 2H) 1.02 (d, *J*=6.8 Hz, 6H) . HRMS, calc'd for C₃₃H₃₅N₅O₂ (M+H), 534.2846; found 534.2864.

- 5 13-5: Analytical LCMS: single peak (214 nm) at 2.343 min (CH₃CN/H₂O/1%TFA, 4 min gradient). ¹H NMR (500 MHz, CD₃OD): δ 7.39 (m, 9H), 7.24 (m, 1H), 7.07 (m, 3H), 4.54 (m, 1H), 4.33 (s, 2H), 3.63 (d, *J*=12.1 Hz, 2H), 3.21 (t, *J*=12.6 Hz, 2H), 2.77 (q, *J*=12.5, 2H), 2.74 (d, *J*=7.0, 2H) 2.29 (m, 1H) 2.07 (d, *J*=13.9 Hz, 2H) 1.02 (d, *J*=6.8 Hz, 6H); HRMS, calc'd for C₃₃H₃₅N₅O₂(M+H), 534.2846; found 534.2864. ^o
- 10 HRMS, calc'd for C₃₃H₃₅N₅O₂ (M+H), 534.2846; found 534.2850.

2020-10-22 04:08:02

5

EXAMPLE 14


10 1-(1-{4-[5-Hydroxy-6-(1H-indol-3-ylmethyl)-3-phenylpyrazin-2-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one 14-1 and 1-(1-{4-[6-Hydroxy-5-(1H-indol-

5 3-ylmethyl)-3-phenylpyrazin-2-yl]benzyl)piperidin-4-yl)-1,3-dihydro-2H-
benzimidazol-2-one 14-2

- 1-4-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylethane-1,2-dione 13-3 (56 mg, 0.1 mmol), L-tryptophan carboxamide (HCl) (24 mg, 0.1 mmol), and K₂CO₃ (28 mg, 0.2 mmol) were dissolved
 10 in 2 mL of EtOH/H₂O (5/1) in an 8 mL vial. The mixture solution is heated at 90°C for 16 hours. After this time, the reaction were cooled and concentrated in vacuo. The crude material was then purified on an Agilent 1100 series Mass Guided HPLC purification system to afford the TFA salts of 14-1 and 14-2 as brown solids.
- 14-1: Analytical LCMS: single peak (214 nm) at 2.381min (CH₃CN/H₂O/1%TFA, 4
 15 min gradient). ¹H NMR (600 MHz, CD₃OD): δ 7.76 (d, J=7.9 Hz 1H), 7.48 (d, J=8.6 Hz, 2H), 7.42 (d, J=8.6 Hz, 2H) 7.32 (d, J=8.0 Hz, 1H), 7.20(m, 6H), 7.07 (m, 5H), 6.99(t, J=7.0 Hz, 1H), 4.53 (m, 1H), 4.34 (s, 2H), 4.30 (s, 2H), 3.57 (d, J=10.5 Hz, 2H), 3.19 (t, J=12.9 Hz, 2H), 2.75 (q, J=12.9, 2H), 2.04 (d,, J=14.1 2H). HRMS, calc'd for C₃₈H₃₄N₆O₂ (M+H),607.2816; found 607.2790.
- 20 14-2: TFA salt as a brown solid. Analytical LCMS: single peak (214 nm) at 2.558min (CH₃CN/H₂O/1%TFA, 4 min gradient). ¹H NMR (500 MHz, CD₃OD): δ 7.76 (d, J=7.9 Hz 1H), 7.48 (d, J=7.7 Hz, 2H), 7.42 (d, J=8.0 Hz, 2H), 7.36 (m, 1H), 7.32 (d, J=8.0 Hz, 1H), 7.23(m, 6H), 7.07 (m, 4H), 6.99(t, J=7.5 Hz, 1H), 4.53 (m, 1H), 4.32 (m, 4H), 3.58 (d, J=11.0 Hz, 2H), 3.19 (t, J=12.9 Hz, 2H), 2.75 (q, J=6.7
 25 Hz, 2H), 2.07 (d,, J=13.9 Hz, 2H). HRMS, calc'd for C₃₈H₃₄N₆O₂ (M+H),607.2816; found 607.2790.


Compounds in Table 2 were synthesized as shown in Examples 13 and 14. The TFA salt of the compound shown was isolated by Mass Guided HPLC purification.

5 Table 2



#	<u>R''</u>	<u>R'''</u>	<u>MS M+1</u>
13-6	-CH ₂ Ph	-OH	568.6
13-7		-OH	534.6
13-8	-OH		558.6

5

EXAMPLE 15

Step 1: 1-(4-{{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl}phenyl}-2-phenylethane-1,2-dione 15-3

10

To an 8 mL vial was placed bromomethyl benzil 15-1 (Toronto Research Chemicals, 500 mg, 1.65 mmol), 4-(2-keto-1-benzimidazoliny)piperidine 15-2 (Aldrich, 358 mg, 1.65 mol), PS-DIEA (887 mg, 3.3 mmol, 3.72 mmol/g) and dry THF (6 mL, 0.3 M).

15



The vial was placed on a GlasCol rotator and allowed to rotate for 2 hours. After this time, the contents of the vial were filtered through a 10 mL BioRad tube, washed with THF and concentrated in vacuo. The crude material was then purified on an Agilent

- 5 1100 series Mass Guided HPLC purification system to afford 775 mg (85%) of the TFA salt of 15-3 as a pale yellow solid. Analytical LCMS: single peak (214 nm) at 2.487 min ($\text{CH}_3\text{CN}/\text{H}_2\text{O}/1\%\text{TFA}$, 4 min gradient). ^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ 10.9 (s, 1H), 8.05 (m, 2H), 7.93 (m, 2H), 7.79 (m, 2H), 7.63 (m, 2H), 7.24 (s, 1H), 6.98 (s, 4H), 4.47 ((s, 2H), 3.5 (m, 2H), 3.2 (m, 3H), 2.61 (q, $J=11$ Hz, 2H), 1.9 (d, $J=11$ Hz, 2H). HRMS, calc'd for $\text{C}_{27}\text{H}_{26}\text{N}_3\text{O}_3$ (M+H), 440.1965; found 440.1968.


Step 2: 1-{1-[4-(3-Phenylquinoxalin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one 15-4

- To an 8 mL vial was placed 1-(4-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylethane-1,2-dione 15-3 (88 mg, 0.16 mmol), 1,2-diaminobenzene (17 mg, 0.16 mol) and dissolved in EtOH (3 mL). The vial was placed in a J-KEM heater/shaker block and warmed to 90 degrees for 9 hours. After this time, the vials were cooled and concentrated in vacuo. The crude material was then purified on an Agilent 1100 series Mass Guided HPLC
- 15 purification system to afford 80 mg (80%) of the TFA salt of 15-4 as a brown solid. Analytical LCMS: single peak (214 nm) at 2.625 min ($\text{CH}_3\text{CN}/\text{H}_2\text{O}/1\%\text{TFA}$, 4 min gradient). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 10.9 (s, 1H), 8.18 (m, 2H), 7.92 (m, 2H), 7.6 (m, 2H), 7.52 (m, 4H), 7.4 (m, 3H), 7.28 (m, 1H), 7.0 (s, 3H), 4.50 (m, 1H), 4.4 (s, 2H), 3.5 (d, $J=12$ Hz, 2H), 3.2 (t, $J=12$ Hz, 2H), 2.6 (q, $J=11.8$ Hz, 2H), 1.94 (d, $J=12$ Hz, 2H). HRMS, calc'd for $\text{C}_{33}\text{H}_{30}\text{N}_5\text{O}$ (M+H), 512.2445; found 512.2443.

5

EXAMPLE 16

16-1



16-2


- 10 3-(4-([4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl)phenyl)-2-phenylquinaxoline-6-carboxylic acid 16-1 and
- 15 2-(4-([4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl)phenyl)-2-phenylquinaxoline-6-carboxylic acid 16-2

To an 8 mL vial was placed 1-(4-([4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl)phenyl)-2-phenylethane-1,2-dione 15-3 (500 mg, 1.1 mmol), 4-carboxy-1,2-diaminobenzene (170 mg, 1.1 mol) and dissolved in EtOH (10 mL). The vial was placed in a J-KEM heater/shaker block and warmed to 90 degrees for 9 hours. After this time, the vials were cooled and concentrated in vacuo. The crude material was then purified on an Agilent 1100 series Mass Guided

- 5 HPLC purification system to afford the TFA salt as a white solid. This protocol afforded a 1:1 mixture of regioisomers 16-1 and 16-2 which were separated by prep HPLC.
- 16-1: Analytical LCMS: single peak (214 nm) at 2.430 min (CH₃CN/H₂O/1%TFA, 4 min gradient). ¹H NMR for 2-1 (400 MHz, DMSO-*d*₆): δ 13.1 (s, 1H), 10.8 (s, 1H), 8.66 (s, 1H), 8.32 (m, 1H), 8.23 (m, 1H), 7.52 (m, 2H), 7.49 (m, 2H), 7.42 (m, 1H), 7.38 (m, 4H), 7.24 (m, 1H), 6.97 (s, 3H), 4.17 (m, 1H), 3.61 (s, 2H), 2.97 (d, *J*=11.4 Hz, 2H), 2.38 (q, *J*=10 Hz, 2H), 2.17 (t, *J*=11.4 Hz, 2H), 1.66 (d, *J*=10 Hz, 2H).
HRMS calc'd for C₃₄H₃₀N₃O₃ (M+H), 556.2343; found 556.2352.
- 10 16-2: Analytical LCMS: single peak (214 nm) at 2.620 min (CH₃CN/H₂O/1%TFA, 4 min gradient). ¹H NMR for 2-1 (400 MHz, DMSO-*d*₆): δ 12.9 (s, 1H), 10.6 (s, 1H), 8.60 (s, 1H), 8.30 (m, 1H), 8.27 (m, 1H), 7.55 (m, 2H), 7.49 (m, 2H), 7.42 (m, 1H), 7.38 (m, 4H), 7.24 (m, 1H), 6.97 (s, 3H), 4.17 (m, 1H), 3.61 (s, 2H), 2.97 (d, *J*=11.4 Hz, 2H), 2.38 (q, *J*=10 Hz, 2H), 2.17 (t, *J*=11.4 Hz, 2H), 1.66 (d, *J*=10 Hz, 2H).
HRMS calc'd for C₃₄H₃₀N₃O₃ (M+H), 556.2343; found 556.2350.
- 15

208040-2280409

5

EXAMPLE 17

10 N-[3-(1H-Imidazol-1-yl)propyl]-3-(4-{{[4-(2-oxo-2,3-dihydro-1H-benzamidazol-1-yl)piperdin-1-yl]methyl}phenyl)-2-phenylquinaxoline-6-carboxamide 17-1

To an 8 mL vial was placed 3-(4-{{[4-(2-oxo-2,3-dihydro-1H-benzamidazol-1-yl)piperdin-1-yl]methyl}phenyl)-2-phenylquinaxoline-6-carboxylic acid 16-1 (35 mg, 0.08 mol), 3-imidazolylpropylamine (10 μ L, 0.08 mol), PS-DCC (110 mg, 0.15 mmol, 1.38 mmol/g), HOBT (15 mg, 0.11 mmol) and DCM (4 mL).




15 The vial was placed on a GlasCol rotator and allowed to rotate overnight. In the morning, MP-carbonate (90 mg, 0.32 mmol, 3.38 mmol/g) was added, and the vial allowed to rotate for another 3 hours. After this time, the vial's contents were filtered through a BioRad tube, washed with DCM and concentrated. The crude material was then purified on an Agilent 1100 series Mass Guided HPLC purification system to

20 afford the bis TFA salt of 17-1 as a brown solid. Analytical LCMS: single peak (214 nm) at 2.090 min ($\text{CH}_3\text{CN}/\text{H}_2\text{O}/1\%\text{TFA}$, 4 min gradient). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 10.9 (s, 1H), 9.1 (s, 1H), 9.0 (t, $J=4.8$ Hz, 1H), 8.71 (s, 1H), 8.29 (s, 2H), 7.84 (s, 1H), 7.69 (2, 1H), 7.55 (m, 7H), 7.3 (s, 1H), 7.0 (s, 3H), 4.51 (m, 1H),

- 5 4.39 (s, 2H), 4.31 (t, $J=6.8$ Hz, 2H), 3.47 (m, 2H), 3.19 (m, 2H), 2.66 (q, $J=11.2$ Hz, 2H), 2.16 (quint, $J=6.8$ Hz, 2H), 1.94 (d, $J=12.4$ Hz, 2H). HRMS calc'd for $C_{40}H_{39}N_8O_2$ ($M+H$), 663.3190; found 663.3191.

EXAMPLE 18

10








- 15 1-{1-[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one 4-1 and 1-{1-[4-(2-phenylpyrido[3,4-b]pyrazin-3-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one 18-2



To an 8 mL vial was placed 1-(4-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)pipepridin-1-yl]methyl}phenyl)-2-phenylethane-1,2-dione 15-3

- 5 (59 mg, 0.10 mmol), 3,4-diaminopyridine (11.1 mg, 0.10 mol) and dissolved in EtOH (3 mL). The vial was placed in a J-KEM heater/shaker block and warmed to 90 degrees for 9 hours. After this time, the vials were cooled and concentrated in vacuo. The crude material was then purified on an Agilent 1100 series Mass Guided HPLC purification system to afford the TFA salts of 18-1 and 18-2 as brown solids.
- 10 18-1: Analytical LCMS: single peak (214 nm) at 2.220 min ($\text{CH}_3\text{CN}/\text{H}_2\text{O}/1\%\text{TFA}$, 4 min gradient). ^1H NMR (400 MHz, CD_3OD): δ 9.64 (d, $J=4$ Hz, 1H), 8.85 (dd, $J=6.2$, 0.9 Hz, 1H), 8.22 (dd, $J=6.1$, 2.0 Hz, 1H), 7.58 (m, 4H), 7.46 (m, 1H), 7.38 (m, 2H), 7.28 (m, 1H), 7.07 (d, $J=2.6$ Hz, 3H), 4.59 (m, 1H), 4.43 (s, 2H), 3.60 (d, $J=12.5$ Hz, 2H), 3.28 (t, $J=11.1$ Hz, 2H), 2.82 (q, $J=12.5$ Hz, 2H), 2.08 (d, $J=13.4$ Hz, 2H).
- 15 HRMS, calc'd for $\text{C}_{32}\text{H}_{29}\text{N}_6\text{O}(\text{M}+\text{H})$, 513.2393; found 512.2393. 18-2: Analytical LCMS: single peak (214 nm) at 2.410 min ($\text{CH}_3\text{CN}/\text{H}_2\text{O}/1\%\text{TFA}$, 4 min gradient). ^1H NMR (400 MHz, CD_3OD): δ 9.60 (d, $J=4$ Hz, 1H), 8.81 (dd, $J=6.2$, 0.9 Hz, 1H), 8.20 (dd, $J=6.1$, 2.0 Hz, 1H), 7.58 (m, 4H), 7.46 (m, 1H), 7.38 (m, 2H), 7.28 (m, 1H), 7.07 (d, $J=2.6$ Hz, 3H), 4.59 (m, 1H), 4.43 (s, 2H), 3.60 (d, $J=12.5$ Hz, 2H), 3.28 (t, $J=11.1$
- 20 Hz, 2H), 2.82 (q, $J=12.5$ Hz, 2H), 2.08 (d, $J=13.4$ Hz, 2H). HRMS, calc'd for $\text{C}_{32}\text{H}_{29}\text{N}_6\text{O}(\text{M}+\text{H})$, 513.2393; found 512.2391.

2020-10-22 09:04:02

5

EXAMPLE 19



5

Step 1: N-benzyloxycarbonyl-2-pyrrolidine-N-methoxy-N-methylcarboxamide
19-3

- 10 N-benzyloxycarbonylproline (25g, 0.116moles) and oxalyl chloride (10.12mL) was dissolved in 310 mL of CH₂Cl₂ and DMF (0.8 mL) and the mixture stirred at room temperature for 2 hours. At the end of this time the solvent was evaporated and the residue was dissolved in 400mL of CH₂Cl₂ and the solution cooled to 0°C. N,O-dimethylhydroxylamine hydrochloride (11.32 g, 0.116 moles) was

5 added, followed by dropwise addition of Et₃N (35.8 mL). The solution was allowed to warm to room temperature and stirred for 2 hours. The reaction mixture was further diluted with 300 mL of CH₂Cl₂ and poured into a bicarbonate solution. The aqueous layer was extracted with CH₂Cl₂ and the combined organic layers were dried over Na₂SO₄ and filtered. The organic solvents were evaporated and the residue
 10 suspended in a EtOAc/CH₂Cl₂/MeOH mixture. The mixture was filtered and the filtrate concentrated under vacuum and redissolved/filtered. The resulting organic soluble residue was purified on a silica gel column (70% EtOAc in hexane) to provide compound 19-3.

15 Step 2: N-benzyloxycarbonyl-2-pyrrolidine carboxaldehyde 19-4

Compound 19-3 (25 g) was dissolved in 200 mL of THF and the solution cooled to 0°C. The solution was flushed with Ar and LiAlH₄ (49 mL of 1M solution) was added and the reaction mixture was stirred for 12 hours. An additional 0.25 eq. of the LiAlH₄ solution was added and the reaction mixture was stirred an
 20 additional 20 minutes. At the end of this time the reaction was quenched by the addition of 2 mL of water and diluted with EtOAc. The aluminum salts were removed by filtration and the filtrate was ashed with potassium sulfate solution, brine and then dried over Mg₂SO₄. The mixture was then filtered and concentrated under vacuum. The residue was purified on a silica gel column (20% EtOAc in hexane) to
 25 provide compound 19-4.

Step 3: 4-chloro-3-methoxybenzaldehyde 19-6

5-Bromo-2-chloroanisole 19-5 (2.2 g) was dissolved in 200 mL of THF and the solution cooled to -78°C. Butyl lithium (4.4 mL of 2.5M solution) was
 30 added slowly, the reaction solution was stirred 5 minutes and DMF (0.93 mL) was added slowly. The reaction mixture was stirred briefly and then poured over sodium bicarbonate and ice. The aqueous mixture was extracted with EtOAc, the organic layer was washed with brine, dried over MgSO₄ and filtered. The filtrate was concentrated under vacuum and the residue then purified by silica gel chromatography
 35 1:9 EtOAc:hexane to provide the aldehyde 19-6 as a white solid..

Step 4: 1-(4-Chloro-3-methoxyphenyl)-2-pyridin-4-yl-ethane-1,2-diol 19-8

To a stirring solution of diisopropylamine (14.4 mL, 110 mmol) in tetrahydrofuran (400 mL) at -78°C was added, dropwise, n-butyllithium (44 mL of a

5 2.5 M solution in tetrahydrofuran). After ten minutes, a solution of 4-pyridylcarbinol *t*-butyldimethylsilyl ether (22.3 g, 100 mmol) in tetrahydrofuran (80 mL) was added dropwise and the temperature allowed to rise to -15°C. The solution was again cooled to -78°C and a solution of 4-chloro-3-methoxybenzaldehyde 19-6 (17 g, 100 mmol) in tetrahydrofuran (60 mL) added dropwise. After the solution was allowed to warm to
 10 room temperature, it was poured into saturated aqueous sodium hydrogen carbonate (2 L). The aqueous layer was extracted with ethyl acetate (3x400 mL), the combined organic layers dried over anhydrous magnesium sulfate, filtered and concentrated at reduced pressure. The resulting oil was dissolved in tetrahydrofuran and to this
 15 solution was added tetrabutylammonium fluoride (120 mL of a 1.0 M solution in tetrahydrofuran) dropwise. After ten minutes, the reaction mixture was concentrated at reduced pressure and the resulting oil chromatographed on silica gel, eluting with 95:5 to 90:10 dichloromethane:methanol to give the title compound as a mixture of diastereomeric diols 19-8 which was used without further purification.

20 Step 5: 1-(3,4-Dichlorophenyl)-2-pyridin-4-yl-ethane-1,2-dione 19-9
 To a stirring solution of methyl sulfoxide (28.7 mL, 403 mmol) in dichloromethane (600 mL) at -78°C was added trifluoroacetic anhydride (42.7 mL, 302 mmol) dropwise. After ten minutes, 1-(4-Chloro-3-methoxyphenyl)-2-pyridin-4-yl-ethane-1,2-diol 19-8 (25.6 g, 91.5 mmol) in dichloromethane (200 mL) was added
 25 dropwise. After another ten minutes, triethylamine (79 mL, 567 mmol) was added dropwise and the reaction mixture immediately warmed to -10°C and poured into water. The aqueous layer was extracted with methylene chloride and the organic layers were combined, dried over anhydrous magnesium sulfate, filtered and concentrated at reduced pressure. The resulting solid was triturated with ether to give
 30 the dione 19-9 as a yellow solid.

Step 6: 2-[5-(4-chloro-3-methoxyphenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-pyrrolidine-1-benzoyloxycarbonyl ester 19-10

Compound 19-4 (2.0 g) and the dione 19-9 (2.76 g) were dissolved in
 35 20 mL of acetic acid and the mixture was heated to 100°C. Ammonium acetate (15.48 g) was added slowly and the reaction mixture stirred for 2 hours. The mixture was then poured into ice and the ice slurry was extracted with 2:1 EtOAc:aqueous NH₄OH. The aqueous layer was extracted 4 times with EtOAc and the combined organic layers were washed with brine and dried over Mg₂SO₄. The mixture was

- 5 filtered and concentrated under vacuum to provide a brown foam. The residue was purified on a silica gel column (3% MeOH in CH₂Cl₂) and the main fractions were repurified under the same silica gel conditions to provide compound 19-10.

10 Step 7: 1-methyl-2-[5-(4-chloro-3-methoxyphenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-pyrrolidine 19-11

- Compound 19-10 (580 mg, 1.19 mmol) was dissolved in 10 mL THF and the solution flushed with Ar. A 1.0 M LiAlH₄ solution (1.79 mL, 1.79 mmol) was added and the reaction mixture was heated to 70°C. After stirring the reaction at 70°C for 2.5 hours an additional 1 equiv. (1.19 mL) of the LiAlH₄ solution was added.
- 15 The reaction was then quenched with of water and the mixture diluted with EtOAc. The mixture was then poured into a saturated sodium bicarbonate solution and the separated aqueous layer was extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried over Mg₂SO₄, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (6% to 10% MeOH in CH₂Cl₂ gradient) to provide the titled compound 19-11.
- 20

EXAMPLE 20

25 Cloning of human Akt1, Akt2, Akt3, ΔPH-Akt1, ΔPH-Akt2, ΔPH-Akt3 and minimal ΔPH Akt1

- The pS2neo vector (deposited in the ATCC on April 3, 2001 as PTA-3253) was prepared as follows: The pRmHA3 vector (prepared as described in *Nucl. Acid Res.* 16:1043-1061 (1988)) was cut with BglII and a 2734 bp fragment was isolated. The pUChsneo vector (prepared as described in *EMBO J.* 4:167-171 (1985))
- 30 was also cut with BglII and a 4029 bp band was isolated. These two isolated fragments were ligated together to generate a vector termed pS2neo-1. This plasmid contains a polylinker between a metallothionein promoter and an alcohol dehydrogenase poly A addition site. It also has a neomycin resistance gene driven by a heat shock promoter. The pS2neo-1 vector was cut with Psp5II and BsiWI. Two
- 35 complementary oligonucleotides were synthesized and then annealed (CTGCGGCCGC (SEQ.ID.NO.: 1) and GTACGCGGCCGCAG (SEQ.ID.NO.: 2)). The cut pS2neo-1 and the annealed oligonucleotides were ligated together to generate a second vector, pS2neo. Added in this conversion was a NotI site to aid in the linearization prior to transfection into S2 cells.

5 Human Akt1 gene was amplified by PCR (Clontech) out of a human spleen cDNA (Clontech) using the 5' primer:
 5'CGCGAATTCAGATCTACCASTEAGCGACGTGGCTATTGTG 3'
 (SEQ.ID.NO.: 3), and the 3' primer:
 5'CGCTCTAGAGGATCCTCAGGCCGTGCTGCTGGC3' (SEQ.ID.NO.: 4). The 5'
 10 primer included an EcoRI and BglII site. The 3' primer included an XbaI and BamHI site for cloning purposes. The resultant PCR product was subcloned into pGEM3Z (Promega) as an EcoRI / Xba I fragment. For expression/purification purposes, a middle T tag was added to the 5' end of the full length Akt1 gene using the PCR primer: 5'GTACGATGCTGAACGATATCTTCG 3' (SEQ.ID.NO.: 5). The resulting
 15 PCR product encompassed a 5' KpnI site and a 3' BamHI site which were used to subclone the fragment in frame with a biotin tag containing insect cell expression vector, pS2neo.

For the expression of a pleckstrin homology domain (PH) deleted (Δ aa 4-129, which includes deletion of a portion of the Akt1 hinge region) version of Akt1
 20 (termed Δ PH-Akt1), PCR deletion mutagenesis was done using the full length Akt1 gene in the pS2neo vector as template. The PCR was carried out in 2 steps using overlapping internal primers
 (5'GAATACATGCCGATGGAAAGCGACAGGGGCTGAAGAGATGGAGGTG 3' (SEQ.ID.NO.: 6), and
 25 5'CCCCTCCATCTCTTCAGCCCCAGTCGCTTTCATCGGCATG TATTC 3' (SEQ.ID.NO.: 7)) which encompassed the deletion and 5' and 3' flanking primers which encompassed the KpnI site and middle T tag on the 5' end. The final PCR product was digested with KpnI and SmaI and ligated into the pS2neo full length Akt1 KpnI / Sma I cut vector, effectively replacing the 5' end of the clone with the
 30 deleted version.

For expression of a minimal Δ PH (Δ aa 1-110) version of Akt1, PCR was performed using full length Akt1 as template and the following PCR oligo primers; 5' PCR oligo =
 5'CGCGGCGCGCCAGGTACCATGGAATACATGCCGATGGAAAAGAAGCAG
 35 GAGGAGGAGGAG 3' (SEQ.ID.NO.: 8)
 which encompassed a KpnI cloning site, the middle T antigen tag and the PH domain deletion. The 3' PCR oligo = 5'CGGAGAACACACGCTCCCGGG 3' (SEQ.ID.NO.: 9).

- 5 The resultant PCR product was digested with KpnI and SmaI and ligated into the pPS2neo full length Akt1 KpnI / SmaI cut vector, effectively replacing the 5' end of the clone with the deleted version.

- Human Akt3 gene was amplified by PCR of adult brain cDNA (Clontech) using the amino terminal oligo primer:
 10 5' GAATTCAGATCTACCATGAGCGATGTTACCATTGTG 3' (SEQ.ID.NO.: 10);
 and the carboxy terminal oligo primer :
 5' TCTAGATCTTATTCTCGTCCACTTGCAGAG 3' (SEQ.ID.NO.: 11).
 These primers included a 5' EcoRI / BglII site and a 3' XbaI / BglII site for cloning
 15 purposes. The resultant PCR product was cloned into the EcoRI and XbaI sites of pGEM4Z (Promega). For expression / purification purposes, a middle T tag was added to the 5' end of the full length Akt3 clone using the PCR primer: 5'
 GGTACCATGGAATACATGCCGATGGAAAGCGATGTTACCATTGTGAAG
 3' (SEQ.ID.NO.: 12). The resultant PCR product encompassed a 5' KpnI site which
 20 allowed in frame cloning with the biotin tag containing insect cell expression vector, pS2neo.

- For expression of a PH domain deleted (Δ aa 4-128, which includes deletion of a portion of the Akt3 hinge region) version of Akt3 (termed Δ PH-Akt3), PCR was performed using the full length Akt3 as template and the following oligo primers;
 25 5'PCR oligo =
 5'CGCAGGTACCATGGAATACATGCCGATGGAAAGCGATGGAGAGGAAGA
 GATGGATGCC 3' (SEQ.ID.NO.: 13) which encompassed a KpnI cloning site, the middle T antigen tag and the deleted PH domain. The 3' PCR oligo =
 5'CGCTCTAGATCTTATTCTCGTCCACTTGCAGAG 3' (SEQ.ID.NO.: 14).
 30 The resultant PCR product was digested with KpnI and BamHI and ligated into the pS2neo full length Akt3 KpnI / BamHI cut vector, effectively replacing the 5' end of the clone with the deleted version.

- Human Akt2 gene was amplified by PCR from human thymus cDNA (Clontech) using the amino terminal oligo primer:
 35 5' AAGCTTAGATCTACCATGAATGAGGTGTCTGTC 3' (SEQ.ID.NO.: 15); and the carboxy terminal oligo primer:
 5'GAATTCGGATCCTCACTCGCGGATGCTGGC 3' (SEQ.ID.NO.: 16). These primers included a 5' HindIII / BglII site and a 3' EcoRI / BamHI site for cloning purposes. The resultant PCR product was subcloned into the HindIII / EcoRI sites of

5 pGem3Z (Promega). For expression / purification purposes, a middle T tag was added to the 5' end of the full length Akt2 using the PCR primer:
 5'GGTACCATGGAATACATGCCGATGGAAAATGAGGTGTCTGTCATCAAAG
 3' (SEQ.ID.NO.: 17). The resultant PCR product was subcloned into the pS2neo vector as described above.

10 For expression of a PH domain deleted (Δ aa 4-131, which includes deletion of a portion of the Akt2 hinge region) version of Akt2 (termed Δ PH-Akt2), PCR was performed using the full length Akt2 gene as template and the following oligo primers; 5' PCR oligo =
 5'CGCAGGTACCATGGAATACATGCCGATGGAAAATGAGACGACTGAGGA
 15 GATGGAAGTGGC 3' (SEQ.ID.NO.: 18), which encompassed a KpnI cloning site, the middle T antigen tag and the deletion. The 3' PCR oligo =
 5'CGCGAATTCGGATCCTCACTCGCGGATGCTGGC 3' (SEQ.ID.NO.: 19). The resultant PCR product was digested with KpnI and SmaI and ligated into the pS2neo full length Akt2 KpnI / SmaI cut vector, effectively replacing the 5' end of the clone
 20 with the deleted version.

EXAMPLE 21

25 Expression of human Akt1, Akt2, Akt3, Δ PH-Akt1, Δ PH-Akt2, Δ PH-Akt3 and minimal Δ PH Akt1

The DNA containing the cloned Akt1, Akt2, Akt3, Δ PH-Akt1, Δ PH-Akt2, Δ PH-Akt3 and Δ PH domain specific-Akt1 genes in the pS2neo expression vector was purified and used to transfect *Drosophila* S2 cells (ATCC) by the calcium phosphate method. Pools of antibiotic (G418, 500 μ g/ml) resistant cells were selected.
 30 Cell were expanded to a 1.0L volume ($\sim 7.0 \times 10^6$ / ml), biotin and CuSO_4 were added to a final concentration of 50 μ M and 50 mM respectively. Cells were grown for 72h at 27°C and harvested by centrifugation. The cell paste was frozen at -70°C until needed.

35

EXAMPLE 22

Purification of human Akt1, Akt2, Akt3, Δ PH-Akt1, Δ PH-Akt2, Δ PH-Akt3 and minimal Δ PH Akt1

208040" 42802E09

5 Cell paste from one liter of S2 cells, described in Example 21, was lysed by sonication with 50mls 1% CHAPS in buffer A: (50mM Tris pH 7.4, 1mM EDTA, 1mM EGTA, 0.2mM AEBSF, 10µg/ml benzamidine, 5µg/ml of leupeptin, aprotinin and pepstatin each, 10% glycerol and 1mM DTT). The soluble fraction was purified on a Protein G Sepharose fast flow (Pharmacia) column loaded with 9mg/ml anti-middle T monoclonal antibody and eluted with 75µM EYMPME (SEQ.ID.NO.: 10 20) peptide in buffer A containing 25% glycerol. Akt/PKB containing fractions were pooled and the protein purity evaluated by SDS-PAGE. The purified protein was quantitated using a standard Bradford protocol. Purified protein was flash frozen on liquid nitrogen and stored at -70°C.

15 Akt and Akt pleckstrin homology domain deletions purified from S2 cells required activation. Akt and Akt pleckstrin homology domain deletions were activated (Alessi et al. *Current Biology* 7:261-269) in a reaction containing 10 nM PDK1 (Upstate Biotechnology, Inc.), lipid vesicles (10 µM phosphatidylinositol-3,4,5-trisphosphate – Metreya, Inc, 100 µM phosphatidylcholine and 100 µM 20 phosphatidylserine – Avanti Polar lipids, Inc.) and activation buffer (50 mM Tris pH7.4, 1.0 mM DTT, 0.1 mM EGTA, 1.0 µM Microcystin-LR, 0.1 mM ATP, 10 mM MgCl₂, 333 µg/ml BSA and 0.1mM EDTA). The reaction was incubated at 22°C for 4 hours. Aliquots were flash frozen in liquid nitrogen.

25 EXAMPLE 23

Kinase Assays

This procedure describes a kinase assay which measures phosphorylation of a biotinylated GSK3-derived peptide by human recombinant 30 active Akt/PKB isoforms or Akt/PKB mutants. The ³³P-labeled biotinylated product can be captured and detected using Streptavidin coated Flashplates (NEN LifeSciences) or Streptavidin Membrane Filter Plates (Promega). Alternatively, a GSK3-derived peptide with 2 added lysine residues was used as the substrate and subsequently captured using Phosphocellulose Membrane Filter Plates 35 (Polyfiltronics).

5

10

15

20

Standard Assay Solutions:

25

30

35

- 5 E. 100X Protease Inhibitor Cocktail (PIC): 1 mg/ml benzamidine, 0.5 mg/ml pepstatin, 0.5 mg/ml leupeptin, 0.5 mg/ml aprotinin.
- F. 3 mM ATP, 200 mM MgCl₂ in H₂O, pH 7.9.
- 10 G. 50% (v/v) Glycerol.
- H. 1% (wt/v) BSA (10 mg/ml) in diH₂O, 0.02% (w/v) NaN₃.
- I. 125 mM EDTA.
- 15 J. 0.75% (wt/v) Phosphoric Acid.
- K. 2.5 M Potassium Chloride.
- 20 L. Tris Buffered Saline (TBS), 25 mM Tris, 0.15 M Sodium Chloride, pH 7.2 (BupH Tris Buffered Saline Pack, Pierce catalog no. 28376).

Procedure for Streptavidin Flash Plate Assay:

25 Step 1:

- A 1 µl solution of the test compound in 100% DMSO was added to 20 µl of 2X substrate solution (20 µM GSK3 Peptide, 300 µM ATP, 20 mM MgCl₂, 20 µCi / ml [³³P] ATP, 1X Assay Buffer, 5% glycerol, 1 mM DTT, 1X PIC, 0.1% BSA and 100 mM KCl). Phosphorylation reactions were initiated by adding 19 µl of 2X Enzyme solution (6.4 nM active Akt/PKB, 1X Assay Buffer, 5% glycerol, 1 mM DTT, 1X PIC and 0.1% BSA). The reactions were then incubated at room temperature for 45 minutes.
- 30

Step 2:

- 35 The reaction was stopped by adding 170 µl of 125 mM EDTA. 200 µl of stopped reaction was transferred to a Streptavidin Flashplate® PLUS (NEN Life Sciences, catalog no. SMP103). The plate was incubated for ≥10 minutes at room temperature on a plate shaker. The contents of each well was aspirated, and the wells rinsed 2 times with 200 µl TBS per well. The wells were then washed 3 times for 5 minutes

- 5 with 200 μ l TBS per well with the plates incubated at room temperature on a platform shaker during wash steps.

The plates were covered with sealing tape and counted using the Packard TopCount as described by the manufacturer for counting [33 P] in Flashplates.

10

Procedure for Streptavidin Filter Plate Assay:

Step 1:

- 15 The enzymatic reactions as described above in Step 1 of the Streptavidin Flash Plate Assay were performed.

Step 2:

- 20 The reaction was stopped by adding 20 μ l of 7.5M Guanidine Hydrochloride. 50 μ l of the stopped reaction was transferred to the Streptavidin filter plate (SAMTM Biotin Capture Plate, Promega, catalog no. V7542) and the reaction was incubated on the filter for 1-2 minutes before applying vacuum.

- 25 The plate was then washed using a vacuum manifold as follows: 1) 4 x 200 μ l/well of 2M NaCl; 2) 6 x 200 μ l/well of 2M NaCl with 1% H_3PO_4 ; 3) 2 x 200 μ l/well of diH_2O ; and 4) 2 x 100 μ l/well of 95% Ethanol. The membranes were then allowed to air dry completely before adding scintillant.

- 30 The bottom of the plate was sealed with white backing tape, 30 μ l/well of Microscint 20 (Packard Instruments, catalog no. 6013621) was added. The top of the plate was sealed with clear sealing tape, and the plate then counted using the Packard TopCount with the appropriate settings for [33 P] with liquid scintillant.

Procedure for Phosphocellulose Filter Plate Assay:

- 35 Step 1:

The enzymatic reactions were performed as described in Step 1 of the Streptavidin Flash Plate Assay (above) utilizing KKGGRARTSSFAEPG (SEQ.ID.NO.: 22) as the substrate in place of biotin-GGRARTSSFAEPG (SEQ.ID.NO.: 21).

5 Step 2:

The reaction was stopped by adding 20 μ l of 0.75% H_3PO_4 . 50 μ l of stopped reaction was transferred to the filter plate (UNIFILTER™, Whatman P81 Strong Cation Exchanger, White Polystyrene 96 Well Plates, Polyfiltronics, catalog no. 7700-3312) and the reaction incubated on the filter for 1-2 minutes before applying vacuum.

10

The plate was then washed using a vacuum manifold as follows: 1) 9 x 200 μ l/well of 0.75% H_3PO_4 ; and 2) 2 x 200 μ l/well of diH_2O . The bottom of the plate was sealed with white backing tape, then 30 μ l/well of Microscint 20 was added. The top of the plate was sealed with clear sealing tape, and the plate counted using the Packard

15

TopCount as described by the manufacturer for counting [^{33}P] and liquid scintillant.

PKA Assay

Each individual PKA assay consists of the following components:

20

- 1) 10 μ l 5X PKA assay buffer (200 mM Tris pH7.5, 100 mM $MgCl_2$, 5mM 2-mercaptoethanol, 0.5 mM EDTA)
- 2) 10 μ l of a 50 μ M stock of Kemptide (Sigma) diluted into water
- 25 3) 10 μ l ^{33}P -ATP (prepared by diluting 1.0 μ l ^{33}P -ATP [10 mCi/ml] into 200 μ l of a 50 μ M stock of unlabeled ATP)
- 4) 10 μ l appropriate solvent control dilution or inhibitor dilution
- 30 5) 10 μ l of a 70 nM stock of PKA catalytic subunit (UBI catalog # 14-114) diluted in 0.5 mg/ml BSA

The final assay concentrations were 40 mM Tris pH 7.5, 20 mM $MgCl_2$, 1 mM 2-mercaptoethanol, 0.1 mM EDTA, 10 μ M Kemptide, 10 μ M ^{33}P -ATP, 14 nM PKA and 0.1 mg/ml BSA.

35

Assays were assembled in 96 deep-well assay plates. Components #3 and #4 were premixed and in a separate tube, a mixture containing equal volumes of

5 components #1, #2, and #5 was prepared. The assay reaction was initiated by adding
30 μ l of the components #1, #2, and #5 mixture to wells containing ^{33}P -ATP and
inhibitor. The liquid in the assay wells was mixed and the assay reactions incubated
for 20 minutes at room temperature. The reactions were stopped by adding 50 μ l of
100 mM EDTA and 100 mM sodium pyrophosphate and mixing.

10

The enzyme reaction product (phosphorylated Kemptide) was
collected on p81 phosphocellulose 96 well filter plates (Millipore) and quantitated.
Each well of a p81 filter plate was filled with 75 mM phosphoric acid. The wells
were aspirated and 170 μ l of 75 mM phosphoric acid was added to each well. A 30 μ l
15 aliquot from each stopped PKA reaction was added to corresponding wells on the
filter plate contained the phosphoric acid. The peptide was trapped on the filter
following the application of a vacuum and the filters were washed 5 times by filling
wells with 75 mM phosphoric acid followed by aspiration. After the final wash, the
filters were allowed to air dry. 30 μ l scintillation fluid was added to each well and the
20 filters counted on a TopCount (Packard).

PKC Assay

Each PKC assay consists of the following components:

25

1) 5 μ l 10X PKC co-activation buffer (2.5 mM EGTA, 4mM CaCl_2)

2) 10 μ l 5X PKC activation buffer (1.6 mg/ml phosphatidylserine, 0.16
mg/ml diacylglycerol, 100 mM Tris pH 7.5, 50 mM MgCl_2 , 5 mM 2-
30 mercaptoethanol)

3) 5 μ l ^{33}P -ATP (prepared by diluting 1.0 μ l ^{33}P -ATP [10 mCi/ml] into
100 μ l of a 100 μ M stock of unlabeled ATP)

35 4) 10 μ l of a 350 μ g/ml stock of myelin basic protein (MBP, UBI) diluted
in water

5) 10 μ l appropriate solvent control or inhibitor dilution

- 5 6) 10 μ l of a 50ng/ml stock of PKC (mix of isoforms from UBI catalog #
14-115) diluted into 0.5 mg/ml BSA

10 Final assay concentrations were as follows: 0.25 mM EGTA, 0.4 mM
CaCl₂, 20 mM Tris pH 7.5, 10 mM MgCl₂, 1 mM 2-mercaptoethanol, 0.32 mg/ml
phosphatidylserine, 0.032 mg/ml diacylglycerol, 10 μ M ³³P-ATP, 70 μ g/ml MBP, 10
ng/ml PKC, 0.1 mg/ml BSA.

15 Assays are performed using 96 deep well assay plates. In each assay
well 10 μ l of solvent control or appropriate inhibitor dilution with 5 μ l ³³P-ATP
(components #5 and #3) were premixed. In a separate tube, a mixture containing
20 equal volumes of components #1, #2, #4, and #6 was prepared. The assay reaction
was initiated by adding 35 μ l of the components #1, #2, #4, and #6 mixture to wells
containing ³³P-ATP and inhibitor. The liquid in the assay wells was thoroughly mixed
and the assay reactions incubated for 20 minutes at room temperature. The reactions
were stopped by adding 100 mM EDTA (50 μ l) and 100 mM sodium pyrophosphate
(50 μ l) and mixing. Phosphorylated MBP was collected on PVDF membranes in 96
well filter plates and quantitated by scintillation counting.

 The results from testing the compounds described in Examples 1-19 in
the assays described above are shown in Table 3:

TABLE 3

	GSK3 Peptide Substrate IC ₅₀ (μM)					Counter screens IC ₅₀ (μM)	
	Akt 1	Akt 1 delta PH	Akt2	Akt2 delta PH	Akt3	PKA	PKC
Compound 1	1.4	>50	>50	>100	>50	>40	>40
Compound 2	0.42	>50	>50	NA	>50	>40	>40
Compound 3	0.91	>50	>50	NA	>50	>40	>40
Compound 4	2.03	>50	>50	NA	>50	>40	>40
Compound 5	0.4	>50	>50	NA	>50	>40	>40
Compound 6	10.5	>50	>50	NA	>50	>40	>40
Compound 7	3.88	>50	>50	NA	>50	>40	>40
Compound 8	15.9	>50	>50	NA	>50	>40	>40
Compound 9	4.65	>50	>50	NA	>50	>40	>40
Compound 10	2.8	>50	20	>100	>50	>80	>80
Compound 11	6.1	>50	45	NA	>100	>80	>80
Compound 12	4.5	>250	115	NA	>250	NA	NA

20201027 14:08:02

5

TABLE 3 (continued)

	Akt 1	Akt 1 delta PH	Akt2	Akt2 delta PH	Akt3	PKA	PKC
Compound 13-6	>50	NA	1.75	NA	3.97	>40	>40
Compound 13-7	>17	NA	4.5	NA	>50	NA	NA
Compound 19-11	51.7	>50	>50	NA	1.4	0.076	0.65

EXAMPLE 24

10 Cell based Assays to Determine Inhibition of Akt/PKB

Cells (for example LnCaP or a PTEN^(-/-) tumor cell line with activated Akt/PKB) were plated in 100mm dishes. When the cells were approximately 70 to 80% confluent, the cells were refed with 5mls of fresh media and the test compound added in solution. Controls included untreated cells, vehicle treated cells and cells treated with either LY294002 (Sigma) or wortmannin (Sigma) at 20 μ M or 200 nM, respectively. The cells were incubated for 2 hrs, and the media removed. The cells were washed with PBS, scraped and transferred to a centrifuge tube. They were pelleted and washed again with PBS. Finally, the cell pellet was resuspended in lysis buffer (20 mM Tris pH8, 140 mM NaCl, 2 mM EDTA, 1% Triton, 1 mM Na Pyrophosphate, 10 mM β -Glycerol Phosphate, 10 mM NaF, 0.5 mM Na_3VO_4 , 1 μ M Microcystine, and 1x Protease Inhibitor Cocktail), placed on ice for 15 minutes and gently vortexed to lyse the cells. The lysate was spun in a Beckman tabletop ultra centrifuge at 100,000 x g at 4°C for 20min. The supernatant protein was quantitated by a standard Bradford protocol (BioRad) and stored at -70°C until needed.

25

Proteins were immunoprecipitated (IP) from cleared lysates as follows: For Akt1/PKB α , lysates are mixed with Santa Cruz sc-7126 (D-17) in NETN (100mM NaCl, 20mM Tris pH 8.0, 1mM EDTA, 0.5% NP-40) and Protein A/G Agarose (Santa Cruz sc-2003) was added. For Akt2/PKB β , lysates were mixed in

- 5 NETN with anti-Akt 2 agarose (Upstate Biotechnology #16-174) and for Akt3/PKB γ , lysates were mixed in NETN with anti-Akt 3 agarose (Upstate Biotechnology #16-175). The IPs were incubated overnight at 4 °C, washed and separated by SDS-PAGE.

- 10 Western blots were used to analyze total Akt, pThr308 Akt, pSer473 Akt, and downstream targets of Akt using specific antibodies (Cell Signaling Technology): Anti-Total Akt (cat. no. 9272), Anti-Phospho Akt Serine 473 (cat. no. 9271), and Anti-Phospho Akt Threonine 308 (cat. no. 9275). After incubating with the appropriate primary antibody diluted in PBS + 0.5% non-fat dry milk (NFDM) at 4 °C overnight, blots were washed, incubated with Horseradish peroxidase (HRP)-
15 tagged secondary antibody in PBS + 0.5% NFDM for 1 hour at room temperature. Proteins were detected with ECL Reagents (Amersham/Pharmacia Biotech RPN2134).

EXAMPLE 25

20 Heregulin Stimulated Akt Activation

- MCF7 cells (a human breast cancer line that is PTEN^{+/+}) were plated at 1x10⁶ cells per 100mm plate. When the cells were 70 – 80% confluent, they were
25 refed with 5 ml of serum free media and incubated overnight. The following morning, compound was added and the cells were incubated for 1 – 2 hrs , heregulin was added (to induce the activation of Akt) for 30 minutes and the cells were analyzed as described above.

EXAMPLE 26

30

Inhibition Of Tumor Growth

In vivo efficacy as an inhibitor of the growth of cancer cells may be confirmed by several protocols well known in the art.

- Human tumor cells from cell lines which exhibit a deregulation of the
35 PI3K pathway (such as LnCaP, PC3, C33a, OVCAR-3, MDA-MB-468 or the like) are injected subcutaneously into the left flank of 8-12 week old female nude mice (Harlan) on day 0. The mice are randomly assigned to a vehicle, compound or combination treatment group. Daily subcutaneous administration begins on day 1 and

- 5 continues for the duration of the experiment. Alternatively, the inhibitor test compound may be administered by a continuous infusion pump. Compound, compound combination or vehicle is delivered in a total volume of 0.1 ml. Tumors are excised and weighed when all of the vehicle-treated animals exhibited lesions of 0.5 - 1.0 cm in diameter, typically 4 to 5.5 weeks after the cells were injected. The
- 10 average weight of the tumors in each treatment group for each cell line is calculated.

5 WHAT IS CLAIMED IS:

1. A method for treating cancer in a mammal in need thereof which comprises administering to said mammal amounts of a selective inhibitor of the activity of one or more of the isoforms of Akt.

10

2. The method according to Claim 1 wherein the selective inhibitor is a small organic molecule.

3. The method according to Claim 1 wherein the selective inhibitor inhibits the phosphorylation of one or more of the isoforms of Akt by upstream kinases and inhibits the phosphorylation of protein targets of an isoform or isoforms of Akt by the activated isoform or isoforms of Akt.

15

4. The method according to Claim 1 wherein the inhibitor is a selective inhibitor of the activity of Akt 1.

20

5. The method according to Claim 1 wherein the inhibitor is a selective inhibitor of the activity of Akt 2.

25

6. The method according to Claim 1 wherein the inhibitor is a selective inhibitor of the activity of Akt 1 and Akt 2.

7. The method according to Claim 1 wherein the inhibitor is a selective inhibitor of the activity of Akt 1 and Akt 3.

30

8. The method according to Claim 1 wherein the inhibitor is a selective inhibitor of the activity of Akt 2 and Akt 3.

9. The method according to Claim 2 wherein the inhibitor is a selective inhibitor of the activity of Akt 3.

35

10. A method for treating cancer in a mammal in need thereof which comprises administering to said mammal amounts of an inhibitor of the activity

208040 22807E09 60370827 040802

5 of one or more of the isoforms of Akt wherein the inhibition by the inhibitor is dependent on the presence of the pleckstrin homology domain of the isoforms of Akt.

10 11. The method according to Claim 10 wherein the inhibitor is a selective inhibitor of the activity of Akt 1.

12. The method according to Claim 10 wherein the inhibitor is a selective inhibitor of the activity of Akt 2.

15 13. The method according to Claim 10 wherein the inhibitor is a selective inhibitor of the activity of Akt 3.

14. The method according to Claim 10 wherein the inhibitor is a selective inhibitor of Akt 1 and Akt 2.

20 15. The method according to Claim 10 wherein the inhibitor is a selective inhibitor of Akt 1 and Akt 3.

25 16. The method according to Claim 10 wherein the inhibitor is a selective inhibitor of Akt 2 and Akt 3.

17. The method according to Claim 10 wherein the inhibitor is a selective inhibitor of Akt 1, Akt 2 and Akt 3.

30 18. A method for treating cancer in a mammal in need thereof which comprises administering to said mammal amounts of an inhibitor of the activity of one or more of the isoforms of Akt wherein the inhibition by the inhibitor is dependent on the presence of the hinge region of the isoforms of Akt.

35 19. The method according to Claim 18 wherein the inhibitor is a selective inhibitor of the activity of Akt 1.

20. The method according to Claim 18 wherein the inhibitor is a selective inhibitor of the activity of Akt 2.

203040-2280409

5 21. The method according to Claim 18 wherein the inhibitor is a selective inhibitor of the activity of Akt 3.

 22. The method according to Claim 18 wherein the inhibitor is a selective inhibitor of Akt 1 and Akt 2.

10

 23. The method according to Claim 18 wherein the inhibitor is a selective inhibitor of Akt 1 and Akt 3.

 22. The method according to Claim 18 wherein the inhibitor is a selective inhibitor of Akt 2 and Akt 3.

15

 23. The method according to Claim 18 wherein the inhibitor is a selective inhibitor of Akt 1, Akt 2 and Akt 3.

20

 24. A method for treating cancer in a mammal in need thereof which comprises administering to said mammal amounts of an inhibitor of the activity of one or more of the isoforms of Akt wherein the inhibition by the inhibitor is dependent on the presence of the pleckstrin homology domain and the hinge region of the isoforms of Akt.

25

 25. The method according to Claim 24 wherein the inhibitor is a selective inhibitor of the activity of Akt 1.

 26. The method according to Claim 24 wherein the inhibitor is a selective inhibitor of the activity of Akt 2.

30

 27. The method according to Claim 24 wherein the inhibitor is a selective inhibitor of the activity of Akt 3.

35

 28. The method according to Claim 24 wherein the inhibitor is a selective inhibitor of Akt-1 and Akt-2.

 29. The method according to Claim 24 wherein the inhibitor is a selective inhibitor of Akt 1, Akt 2 and Akt 3.

5 lack their pleckstrin homology domains.

37. A method for identifying a compound that is a selective inhibitor of one, two or three of the Akt isoforms, whose inhibitory efficacy is dependent on the pleckstrin homology domain, that comprises the steps of:

- 10 d) determining the efficacy of a test compound in inhibiting the activity of an Akt isoform;
- e) determining the efficacy of the test compound in inhibiting the activity of the Akt isoform that has been modified to delete the pleckstrin homology domain; and
- 15 f) comparing the activity of the test compound against the Akt isoform with the activity of the test compound against the modified Akt isoform lacking the pleckstrin homology domain.

38. A method for identifying a compound that is a selective inhibitor of one, two or three of the Akt isoforms, whose inhibitory efficacy is dependent on the hinge region of Akt, that comprises the steps of:

- 20 e) determining the efficacy of a test compound in inhibiting the activity of an Akt isoform;
- f) determining the efficacy of the test compound in inhibiting the activity of the Akt isoform that has been modified to delete the pleckstrin homology domain;
- 25 g) determining the efficacy of the test compound in inhibiting the activity of the Akt isoform that has been modified to delete the pleckstrin homology domain and the hinge region; and
- 30 h) comparing the activity of the test compound against the Akt isoform, the activity of the test compound against the modified Akt isoform lacking the PH domain, and the activity of the test compound against the modified Akt isoform lacking the pleckstrin homology domain and the hinge region.

35

39. A modified Akt isoform lacking only the pleckstrin homology domain.

40. A modified Akt isoform lacking only the hinge region.

5

41. A modified Akt isoform lacking the full pleckstrin
homology domain and the full hinge region.

5 TITLE OF THE INVENTION
A METHOD OF TREATING CANCER

ABSTRACT OF THE DISCLOSURE

- 10 The present invention is directed to a method of treating cancer which comprises administration of a compound which selectively inhibits the activity of one or two of the isoforms of Akt, a serine/threonine protein kinase. The invention is particularly directed to the method wherein the compound is dependent on the presence of the pleckstrin homology domain of Akt for its inhibitory activity.